Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments


Validive



®



Phase 2b/3 VOICE Trial Anticipates Go/No-Go Interim Readout by End of Next Week



Camsirubicin Phase 1b Dose-Escalation Trial Now Enrolling 5th Dose-Level Cohort (650 mg/m



2



)

WILMETTE, Ill., March 23, 2023 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced fourth quarter and full-year 2022 financial results and summarized recent developments.

Recent Developments


Validive – International Phase 2b/3 Trial, Interim Go/No-go Analysis on Track for End of Next Week

  • The VOICE trial, in planning for a potential positive go/no-go outcome from the interim analysis, continues to enroll patients in the Phase 3 portion of the VOICE trial and add additional clinical sites (now at 81 active sites across the U.S. and Europe).
  • The blinded interim analysis of clinical data from the Phase 2b patient cohort of the trial, to be performed by an independent data monitoring committee, will be used to recommend the Company either continue enrolling the Phase 3 portion of the trial or to stop the trial. This analysis should be completed and reported out by the end of next week.


Camsirubicin – Phase 1b Dose-Escalation Trial, Now Enrolling Fifth Dose-Level Cohort

  • Monopar is currently enrolling patients into the fifth dose-level cohort (650 mg/m2), which is nearly 2.5x the highest dose evaluated in any prior camsirubicin clinical trial (265mg/m2).
  • Phase 1b data to date show an improvement in median progression free survival from what was observed in the prior camsirubicin Phase 2 trial (265 mg/m2). This is supportive of our dose-response hypothesis with camsirubicin.
  • To date, no drug-related cardiotoxicity has been observed with camsirubicin treatment as evaluated by the industry standard left-ventricular ejection fraction (LVEF). This compares favorably to the well-documented dose-restricting cardiotoxicity experienced with doxorubicin, the current first-line treatment for advanced soft tissue sarcoma (ASTS).
  • 75% of camsirubicin patients in this trial have experienced no hair loss. Of the 25% with any hair loss, only 8% experienced >50% hair loss and only 17% experienced low grade hair loss. This compares favorably to the approximately 50% of doxorubicin treated patients in recent ASTS clinical trials reporting some amount of hair loss, with the majority of these patients experiencing >50% hair loss.
  • Only 8% of camsirubicin patients in the trial have experienced low grade, mild oral mucositis. This compares favorably to the roughly 35-40% of doxorubicin treated patients in recent ASTS clinical trials that experienced mild-to-severe oral mucositis.


MNPR-101 for Radiopharmaceutical Use – Promising Preclinical Studies Support FIH Study

  • MNPR-101-Zr is a zirconium-89 labeled version of MNPR-101, a highly selective antibody against the urokinase plasminogen activator receptor (uPAR). Positron emission tomography (PET) imaging of preclinical mouse models for triple-negative breast, colorectal, and pancreatic tumors displayed high and selective uptake of MNPR-101-Zr in these uPAR-expressing tumors.
  • Based on the promising recently generated preclinical imaging results with MNPR-101-Zr, Monopar and its collaborator, NorthStar Medical Radioisotopes, LLC committed to additional funding with the aim of initiating a first-in-human (FIH) imaging study with MNPR-101-Zr as early as the end of this year.
  • These proof-of-concept studies provide support for a FIH PET imaging study with MNPR-101-Zr and a future therapeutic study using the previously announced actinium-225 labeled radioimmunotherapeutic version of MNPR-101. Overall, the imaging results demonstrate the potential utility of MNPR-101 as a precision targeting agent for both imaging and therapy in multiple cancer indications.


MNPR-202 – Promising Preclinical Data Ignites Further Research

  • MNPR­202 is designed to retain the same potentially non­cardiotoxic backbone as camsirubicin but is modified at other positions which may enable it to work in certain cancers that are resistant to camsirubicin and doxorubicin.
  • Monopar’s collaborator at the National University of Singapore, Cancer Science Institute, has reported data from blood cancer preclinical studies showing that MNPR-202:

    – has a similar cytotoxic potency to doxorubicin
    – generates increased DNA damage in the cancer cells compared to doxorubicin
    – has a unique immune activation profile versus doxorubicin
    – demonstrates increased apoptosis (programmed cell death) compared to doxorubicin
    – causes a distinct set of genes to be upregulated and downregulated versus doxorubicin and
    – may also be superior to doxorubicin in certain combination treatment regimens.

  • A combination drug screen with 183 compounds was performed, revealing distinct differences in the synergy profile between doxorubicin and MNPR-202 when used along with other compounds. For example, MNPR-202 demonstrated a more favorable synergy profile with the experimental anti-cancer agent volasertib compared to doxorubicin.


Kim R. Tsuchimoto Appointed as New Board Member

  • On March 20, 2023, the Company increased its Board size from five to six members.
  • Simultaneously, Monopar appointed Kim R. Tsuchimoto, the Company’s Chief Financial Officer, to the Board to serve until the next annual stockholders’ meeting.
  • Ms. Tsuchimoto brings over 25 years of experience in the biopharma industry, which includes previously serving as Vice President at BioMarin Pharmaceutical and Chief Financial Officer at Raptor Pharmaceutical. She was involved in BioMarin’s initial public offering onto Nasdaq in 1999, Raptor’s reverse merger onto Nasdaq in 2009, and Monopar’s initial public offering onto Nasdaq in 2019. She brings strong financial management, corporate governance and financial strategy experience to Monopar’s Board.


Results for the Fourth Quarter and Year Ended December 31, 2022, Compared to the Fourth Quarter and Year Ended December 31, 2021


Cash and Net Loss

Cash, cash equivalents and short-term investments as of December 31, 2022, were $13.1 million. Monopar expects that its current funds will be sufficient for Monopar to obtain topline results from its ongoing open-label Phase 1b camsirubicin clinical trial as planned by the end of 2023 (but this may not be the case if camsirubicin reaches even higher dose levels than anticipated and topline results are deferred as dosing continues beyond 2023) and the continued enrollment in the Phase 3 portion of the ongoing Validive Phase 2b/3 (VOICE) clinical program should the interim analysis yield a “go” decision. Monopar will require additional funding and/or a corporate partner to advance its clinical and preclinical programs and anticipates that it will seek to raise additional capital and/or engage a partner within the next 12 months to fund its future operations.

Net loss for the fourth quarter of 2022 was $2.9 million or $0.22 per share compared to net loss of $2.7 million or $0.21 per share for the fourth quarter of 2021. Net loss for the year ended December 31, 2022 was $10.5 million or $0.83 per share compared to net loss of $9.1 million or $0.73 per share for the year ended December 31, 2021.


Research and Development (R&D) Expenses

R&D expenses for the fourth quarter of 2022 were $2.1 million compared to $2.0 million for the fourth quarter of 2021. This increase of $0.1 million was primarily due to 1) an increase of $0.3 million for VOICE clinical trial expenses, and 2) an increase in $0.1 million in R&D consulting partially offset by a decrease of $0.3 million in R&D personnel expenses.

R&D expenses for the year ended December 31, 2022 were $7.6 million compared to $6.5 million for the year ended December 31, 2021. This increase of $1.1 million was primarily due to 1) an increase of $1.0 million for VOICE clinical trial expenses, 2) an increase of $0.5 million for camsirubicin Phase 1b clinical trial expenses, and 3) increase of $0.2 million in R&D consulting partially offset by 1) a decrease of $0.5 million in R&D personnel expenses and 2) a decrease of $0.1 million in preclinical program expenses.


General and Administrative (G&A) Expenses

G&A expenses for the fourth quarter of 2022 were $0.8 million, compared to $0.7 million for the fourth quarter of 2021. This increase of $0.1 million was primarily due to an increase in G&A personnel expenses.

G&A expenses for the year ended December 31, 2022 were $2.9 million, compared to $2.6 million for the year ended December 31, 2021. This increase of $0.3 million was primarily due to an increase in G&A personnel expenses.

About Monopar Therapeutics

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar’s pipeline consists of Validive® (Phase 2b/3) for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for radiopharmaceutical use in advanced cancers; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, and links to SEC filings that contain detailed financial information, visit: https://ir.monopartx.com/annual-reports

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include statements concerning: Monopar’s plans to continue to activate Validive clinical sites in both the U.S. and Europe; that the VOICE trial interim analysis should be completed and reported out by the end of next week; that Monopar and its collaborator, NorthStar Medical Radioisotopes, LLC are aiming to initiate a first-in-human imaging study with MNPR-101-Zr as early as the end of this year; and that Monopar expects that its current funds will be sufficient for Monopar to obtain topline results from its ongoing open-label Phase 1b camsirubicin clinical trial as planned by the end of 2023 (but this may not be the case if camsirubicin reaches even higher dose levels than anticipated and topline results are deferred as dosing continues beyond 2023) and the continued enrollment in the Phase 3 portion of the ongoing Validive Phase 2b/3 (VOICE) clinical program. The forward-looking statements involve risks and uncertainties including, but not limited to: not completing and reporting out the VOICE trial interim analysis by the end of next week; reaching a no-go decision based on the interim analysis; uncertainty of the continuation of the Validive program if the interim analysis is negative; if the interim analysis is positive, not successfully recruiting patients and initiating additional clinical trial sites for the Phase 3 portion of the VOICE trial or the camsirubicin Phase 1b clinical trial within expected timeframes, if at all; the camsirubicin trial data being inconclusive or negative; the Company’s inability to raise sufficient funds or engage a partner to complete the Phase 3 portion of the VOICE clinical trial and continue the camsirubicin clinical program through and beyond the Phase 1b clinical trial; potential ramifications due to recent instability in the banking industry; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Contact

Kim R. Tsuchimoto
Chief Financial Officer
[email protected] 

Follow Monopar on social media for updates: 
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics



‘Refounded’ Ford to Show How Customer-Focused Segments Will Drive Value and Growth, Changes in Financial Reporting

‘Refounded’ Ford to Show How Customer-Focused Segments Will Drive Value and Growth, Changes in Financial Reporting

  • Says results will now be reported by Ford Blue (iconic gas, hybrid vehicles), Ford Model e (breakthrough EVs) and Ford Pro (commercial products, services), not by regional markets
  • Believes Ford+ will produce solid growth and sustained, healthy profitability and returns by deploying new technologies, achieving higher quality, lowering costs and complexity
  • Reconfirms late-2026 margin targets of 10% for company adjusted EBIT and 8% for Ford Model e – the latter driven by ambitious scaling of EV production run rates
  • Points to Ford Pro as a powerful illustration of how customer-relevant, software-enabled vehicles and services will generate value across all three segments
  • Reaffirms full-year 2023 adjusted EBIT guidance of $9 billion to $11 billion; provides segment-level outlooks; plans to share more information at Capital Markets Day on May 22

NEW YORK–(BUSINESS WIRE)–
Ford today will walk investors, analysts and others through how the company is now organized and operating – and will report financial results – based on three new global business segments that are focused on different automotive customers, rather than by geographic regions.

Leaders will also summarize ways that the segments will deliver exceptional value to their respective customers and, together, for other Ford stakeholders: Ford Blue with iconic gas and hybrid vehicles, Ford Model e via breakthrough digital capabilities and electric vehicles, and Ford Pro with products and services to help commercial customers maximize their operations.

The “teach-in” event will be held at 10:00 a.m. Eastern Time at the New York Stock Exchange and streamed, “live” and on replay, via shareholder.ford.com.

“We’ve essentially ‘refounded’ Ford, with business segments that provide new degrees of strategic clarity, insight and accountability to the Ford+ plan for growth and value,” CFO John Lawler said. “It’s not only about changing how we report financial results; we’re transforming how we think, make decisions and run the company, and allocate capital for highest returns.”

Lawler said the teach-in will help investors and analysts develop new models for projecting, tracking and valuing the individual and collective performances of Ford’s new segments, after decades of the business being managed and reporting financial results by regional markets.

Ford Controller Cathy O’Callaghan will highlight how three principles guided the new segmentation:

  1. Fairly representing the business models of each segment
  2. Giving the Ford Blue, Ford Model e and Ford Pro teams both the latitude and accountability for their success, and
  3. Being easy to understand and simple to execute, so that everyone can see how Ford is generating value for customers and other stakeholders.

“This wasn’t a simple proforma spreadsheet exercise,” O’Callaghan said. “It represents nearly a year of disciplined work by hundreds of Ford people to help us capture the huge strategic opportunity of Ford+ and provide unique transparency into our business.”

During the event and in supporting material available online – including recast segment results for 2022 by quarter and full-year 2021 (summary attached) – Ford will explain how assets are assigned and revenue and costs are reported across the segments. The company will also describe accounting for products supplied between segments. For example, vehicles sold by Ford Pro to its commercial customers will be manufactured by Ford Blue or Ford Model e.

Additionally, Ford today will:

  • Reiterate a 10% margin target for company adjusted EBIT (earnings before interest and taxes) by the end of 2026
  • Confirm that, among the new business segments, Ford Blue and Ford Pro are both solidly profitable and well-positioned for growth
  • Repeat its 8% EBIT margin objective by late 2026 for Ford Model e, which is tied to planned global electric vehicle production run rates of 600,000 units by the end of 2023 and two million by the end of 2026
  • Say that the contribution margin of Ford Model e’s first-generation EVs – representing revenue minus certain variable costs – is expected to approach break-even this year, but be more than offset on an EBIT basis by higher investments in new EV products and manufacturing capacity
  • Reiterate that it anticipates full-year adjusted EBIT to be $9 billion to $11 billion – and adjusted free cash flow to be about $6 billion – based on assumptions outlined in the fourth-quarter 2022 earnings release on Feb. 2, and
  • Provide 2023 segment-level EBIT expectations: about $7 billion for Ford Blue, a modest improvement from last year; a full-year loss of about $3 billion for Ford Model e; and EBIT approaching $6 billion for Ford Pro, nearly twice its 2022 earnings.

Ford plans to announce first-quarter results on Tuesday, May 2.

On May 22, Ford will host its next Capital Markets Day in Dearborn. On that day, executives will provide extensive updates on the strategic potential and progress of Ford+ and the company’s rapidly expanding capabilities in software and services, along with deep dives into plans and key performance indicators for each of the business segments.

About Ford Motor Company

Ford Motor Company (NYSE: F) is a global company based in Dearborn, Michigan, committed to helping build a better world, where every person is free to move and pursue their dreams. The company’s Ford+ plan for growth and value creation combines existing strengths, new capabilities and always-on relationships with customers to enrich experiences for customers and deepen their loyalty. Ford develops and delivers innovative, must-have Ford trucks, sport utility vehicles, commercial vans and cars and Lincoln luxury vehicles, along with connected services. The company does that through three customer-centered business segments: Ford Blue, engineering iconic gas-powered and hybrid vehicles; Ford Model e, inventing breakthrough EVs along with embedded software that defines exceptional digital experiences for all customers; and Ford Pro, helping commercial customers transform and expand their businesses with vehicles and services tailored to their needs. Additionally, Ford is pursuing mobility solutions through Ford Next, and provides financial services through Ford Motor Credit Company. Ford employs about 173,000 people worldwide. More information about the company and its products and services is available at corporate.ford.com.

Adjusted EBIT is a non-GAAP financial measure. Ford does not provide guidance on a net income basis, the comparable GAAP measure. Ford’s net income in 2023 will include potentially significant special items that have not yet occurred and are difficult to predict with reasonable certainty, including gains and losses on pension and OPEB remeasurements.

Adjusted free cash flow is a non-GAAP financial measure. Ford does not provide guidance for net cash provided by/(used in) operating activities, the comparable GAAP measure. Ford’s net cash provided by/(used in) operating activities in 2023 will include potentially significant special items that have not yet occurred and are difficult to predict with reasonable certainty, including cash flows related to the Company’s exposures to foreign currency exchange rates and certain commodity prices (separate from any related hedges), Ford Credit’s operating cash flows, and cash flows related to special items, including separation payments, each of which individually or in the aggregate could have a significant impact to our net cash provided by/(used in) our operating activities.

Contribution margin is calculated by subtracting material, warranty, freight and duty expenses from revenue.

Cautionary Note on Forward-Looking Statements

Statements included or incorporated by reference herein may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on expectations, forecasts, and assumptions by our management and involve a number of risks, uncertainties, and other factors that could cause actual results to differ materially from those stated, including, without limitation:

  • Ford and Ford Credit’s financial condition and results of operations have been and may continue to be adversely affected by public health issues, including epidemics or pandemics such as COVID-19;
  • Ford is highly dependent on its suppliers to deliver components in accordance with Ford’s production schedule and specifications, and a shortage of or inability to acquire key components, such as semiconductors, or raw materials, such as lithium, cobalt, nickel, graphite, and manganese, can disrupt Ford’s production of vehicles;
  • To facilitate access to the raw materials necessary for the production of electric vehicles, Ford has entered into, and expects to continue to enter into, multi-year commitments to raw material suppliers that subject Ford to risks associated with lower future demand for such materials as well as costs that fluctuate and are difficult to accurately forecast;
  • Ford’s long-term competitiveness depends on the successful execution of Ford+;
  • Ford’s vehicles could be affected by defects that result in delays in new model launches, recall campaigns, or increased warranty costs;
  • Ford may not realize the anticipated benefits of existing or pending strategic alliances, joint ventures, acquisitions, divestitures, restructurings, or new business strategies;
  • Operational systems, security systems, vehicles, and services could be affected by cyber incidents, ransomware attacks, and other disruptions and impact Ford and Ford Credit as well as their suppliers and dealers;
  • Ford’s production, as well as Ford’s suppliers’ production, and/or the ability to deliver products to consumers could be disrupted by labor issues, natural or man-made disasters, adverse effects of climate change, financial distress, production difficulties, capacity limitations, or other factors;
  • Ford’s ability to maintain a competitive cost structure could be affected by labor or other constraints;
  • Ford’s ability to attract and retain talented, diverse, and highly skilled employees is critical to its success and competitiveness;
  • Ford’s new and existing products and digital, software, and physical services are subject to market acceptance and face significant competition from existing and new entrants in the automotive and digital and software services industries and its reputation may be harmed if it is unable to achieve the initiatives it has announced;
  • Ford’s results are dependent on sales of larger, more profitable vehicles, particularly in the United States;
  • With a global footprint, Ford’s results could be adversely affected by economic or geopolitical developments, including protectionist trade policies such as tariffs, or other events;
  • Industry sales volume can be volatile and could decline if there is a financial crisis, recession, or significant geopolitical event;
  • Ford may face increased price competition or a reduction in demand for its products resulting from industry excess capacity, currency fluctuations, competitive actions, or other factors;
  • Inflationary pressure and fluctuations in commodity and energy prices, foreign currency exchange rates, interest rates, and market value of Ford or Ford Credit’s investments, including marketable securities, can have a significant effect on results;
  • Ford and Ford Credit’s access to debt, securitization, or derivative markets around the world at competitive rates or in sufficient amounts could be affected by credit rating downgrades, market volatility, market disruption, regulatory requirements, or other factors;
  • The impact of government incentives on Ford’s business could be significant, and Ford’s receipt of government incentives could be subject to reduction, termination, or clawback;
  • Ford Credit could experience higher-than-expected credit losses, lower-than-anticipated residual values, or higher-than-expected return volumes for leased vehicles;
  • Economic and demographic experience for pension and OPEB plans (e.g., discount rates or investment returns) could be worse than Ford has assumed;
  • Pension and other postretirement liabilities could adversely affect Ford’s liquidity and financial condition;
  • Ford and Ford Credit could experience unusual or significant litigation, governmental investigations, or adverse publicity arising out of alleged defects in products, services, perceived environmental impacts, or otherwise;
  • Ford may need to substantially modify its product plans and facilities to comply with safety, emissions, fuel economy, autonomous driving technology, environmental, and other regulations;
  • Ford and Ford Credit could be affected by the continued development of more stringent privacy, data use, and data protection laws and regulations as well as consumers’ heightened expectations to safeguard their personal information; and
  • Ford Credit could be subject to new or increased credit regulations, consumer protection regulations, or other regulations.

We cannot be certain that any expectation, forecast, or assumption made in preparing forward-looking statements will prove accurate, or that any projection will be realized. It is to be expected that there may be differences between projected and actual results. Our forward-looking statements speak only as of the date of their initial issuance, and we do not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events, or otherwise. For additional discussion, see “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, as updated by our subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

.

Media

T.R. Reid

1.313.319.6683

[email protected]

Equity Investment Community

Lynn Antipas Tyson

1.914.485.1150

[email protected]

Fixed-Income Investment Community

Jessica Vila-Goulding

1.313.248.3896

[email protected]

Shareholder Inquiries

1.800.555.5259 or

1.313.845.8540

[email protected]

KEYWORDS: United States North America Michigan New York

INDUSTRY KEYWORDS: EV/Electric Vehicles Alternative Vehicles/Fuels Automotive Automotive Manufacturing General Automotive Performance & Special Interest Vehicle Technology Manufacturing

MEDIA:

Logo
Logo

LGI Homes Announces Grand Opening of New Community Near Atlanta

CONYERS, Ga., March 23, 2023 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ:LGIH) today announced the opening of a new community in the Atlanta, Georgia market, Avondale North.

Avondale North by LGI Homes is located in Conyers, a quaint town on the southeast side of Atlanta. Here, homeowners will enjoy exploring the small town atmosphere, as well as the surrounding areas. Just ten minutes from the community is Old Town Conyers, an entertainment district and popular TV show filming site. Homebuyers will enjoy all of this while still having easy access to downtown Atlanta.

LGI Homes at Avondale North provides homeowners with all the amenities the modern family is searching for. Families can look forward to creating memories that last a lifetime in the community park complete with a children’s playground and a pavilion with a grill. When the kids are looking for a place to cool off, there will be no better place than the neighborhood splash pad. Homebuyers can grab their neighbors and start a game on the multi-use field or the half-court sports court. Every day is a new adventure at Avondale North!

Avondale North offers an array of brand-new, one- and two-story homes. Here, there are five spacious floor plans ranging from three to four bedrooms with two to two and a half bathrooms. Each new home comes equipped with LGI Homes’ CompleteHome™ interior package, with upgrades including granite countertops, a full suite of energy-efficient Whirlpool® appliances, luxury vinyl plank flooring, and professional front yard landscaping, all at no additional cost. Paired with these spectacular upgrades, the floor plan lineup also showcases spacious family rooms, chef-ready kitchens, and open-concept layouts.

New homes at Avondale North are priced from the low-$300s. For additional information or to schedule a tour, interested homebuyers are encouraged to call (866) 888-6481 ext 533 or visit LGIHomes.com/AvondaleNorth.

About LGI Homes, Inc.

LGI Homes, Inc. is a pioneer in the homebuilding industry, successfully applying an innovative and systematic approach to the design, construction and sale of homes. As one of America’s fastest growing companies, LGI Homes has a notable legacy of more than 19 years of homebuilding excellence, over which time it has closed more than 50,000 homes and has been profitable every year. Headquartered in The Woodlands, Texas, LGI Homes has operations across 35 markets in 20 states and, since 2018, has been ranked as the 10th largest residential builder in the United States based on units closed. Nationally recognized for its quality construction and exceptional customer service, LGI Homes’ commitment to excellence extends to its more than 900 employees, earning the Company numerous workplace awards at the local, state and national level, including Top Workplaces USA’s 2022 Cultural Excellence Award. For more information about LGI Homes and its unique operating model focused on making the dream of homeownership a reality for families across the nation, please visit the Company’s website at www.lgihomes.com.

MEDIA CONTACT:

Rachel Eaton
(281) 362-8998 ext. 2560

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/67311b75-95b7-46dd-8371-8263e789c7ae



Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines

Collaboration will extend the applications of each company’s platform through discovery and development of novel lipid nanoparticles using Generation Bio’s proprietary stealth cell-targeted lipid nanoparticle (ctLNP) delivery system

Moderna has acquired an option to license Generation Bio’s ctLNP and closed-ended DNA (ceDNA) technology for two immune cell programs and two liver programs, with an additional option for a third immune cell or liver program

Moderna will fund all research and development activities under the collaboration

Generation Bio will receive a $40 million upfront cash payment, a pre-payment of research funding, plus a $36 million equity investment from Moderna, with the potential for additional milestones, fees, and royalties

CAMBRIDGE, Mass., March 23, 2023 (GLOBE NEWSWIRE) — Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced that the two companies have entered into a strategic collaboration to combine Moderna’s biological and technical expertise with core technologies of Generation Bio’s non-viral genetic medicine platform. The collaboration aims to expand the application of each company’s platform by developing novel nucleic acid therapeutics, including those capable of reaching immune cells, to accelerate their respective pipelines of non-viral genetic medicines.

“Moderna continues to invest in innovative technology to enable us to develop a breadth of transformative medicines for patients,” said Rose Loughlin, Ph.D., Moderna’s Senior Vice President for Research and Early Development. “Through this collaboration, which builds on Generation Bio’s non-viral genetic medicines platform, we have the potential to target immune cells with diverse nucleic acid cargos and the liver for gene replacement. We are excited to have Generation Bio as our partner as we continue to broaden our therapeutic pipeline and extend the potential benefit of nucleic acid therapeutics to more patients.”

“Non-viral DNA therapeutics may offer durable, redosable, titratable genetic medicines to patients suffering from rare and prevalent diseases on a global scale,” said Phillip Samayoa, Ph.D., Chief Strategy Officer of Generation Bio. “This collaboration represents a foundational investment in our platform science, both deepening our pipeline of rare and prevalent liver disease programs beyond hemophilia A and accelerating our work to reach outside of the liver with nucleic acid therapies. We are thrilled to collaborate with Moderna to extend genetic medicines to new tissues and cell types through the joint development of novel targeting for our stealth ctLNPs to reach immune cells.”

About the Collaboration

Under the terms of the agreement, Moderna may advance two immune cell programs, each of which may use a jointly developed ctLNP to deliver ceDNA. In addition, Moderna may advance two liver programs, each of which may use a liver-targeted ctLNP developed by Generation Bio to deliver ceDNA. Moderna retains an option to license a third program for either immune cells or the liver.

Generation Bio will receive a $40 million upfront cash payment and a $36 million equity investment issued at a premium over recent share prices. Moderna will fund all collaboration work, including a research pre-payment. Generation Bio is also eligible for future development, regulatory and commercial milestone payments, as well as royalties on global net sales of liver-targeted and immune cell-targeted products commercialized under the agreement. The agreement additionally provides Moderna with the right, subject to certain terms and conditions, to purchase additional shares of common stock in connection with a future equity financing by Generation Bio.

Further, Moderna and Generation Bio will both leverage collaboration research to continue to advance in vivo immune cell targeting as a new class of genetic medicines, with downstream economics on products utilizing such technology. Generation Bio is eligible to receive certain exclusivity fees as well as potential development and regulatory milestones and royalties on products that Moderna advances using ctLNP technology developed under the collaboration.

About Moderna

In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past eight years. To learn more, visit www.modernatx.com.

Moderna Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the terms of the research collaboration between Moderna and Generation Bio to develop novel nucleic acid therapeutics, including the potential to target immune cells with diverse nucleic acid cargos and the liver for gene replacement; the targets to be developed under the collaboration; the funding to be paid by Moderna upon initiation of the collaboration and upon reaching certain milestones; and Moderna’s $36 million equity investment in Generation Bio. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

About Generation Bio  

Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. This approach is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues and cell types, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio’s manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world. 

For more information, please visit www.generationbio.com

Generation Bio Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the company, including statements about our strategic plans or objectives, our technology platform, our research and clinical development plans, and the potential benefits and results that may be achieved through the collaboration with Moderna and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: that the anticipated benefits and potential of Generation Bio’s collaboration with Moderna may not be achieved on the anticipated timeline, or at all; that data may not support further development of the therapies subject to the collaboration due to safety, efficacy, or other reasons; uncertainties inherent in the identification and development of product candidates, including the conduct of research activities, the initiation and completion of preclinical studies and clinical trials and clinical development of the company’s product candidates; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; whether results from earlier preclinical studies will be predictive of the results of later preclinical studies and clinical trials; uncertainties regarding the RES manufacturing process; uncertainties regarding the company’s ability to assign or sublease its manufacturing property; expectations for regulatory approvals to conduct trials or to market products; challenges in the manufacture of genetic medicine products; whether the company’s cash resources are sufficient to fund the company’s operating expenses and capital expenditure requirements for the period anticipated; the ongoing impact of the COVID-19 pandemic on the company’s business and operations; expectations for regulatory approvals to conduct trials or to market products; as well as the other risks and uncertainties set forth in the “Risk Factors” section of our most recent annual report on Form 10-K, which is on file with the Securities and Exchange Commission, and in subsequent filings the company may make with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the company’s views as of the date hereof. The company anticipates that subsequent events and developments will cause the company’s views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date on which they were made.

Moderna Contacts

Media:

Mary Beth Woodin
Senior Director, R&D Communications
[email protected]
617-899-3991

Investors:

Lavina Talukdar
Senior Vice President & Head of Investor Relations
[email protected]
617-209-5834

Generation Bio Contact

Investors and Media

Maren Killackey
Generation Bio
[email protected]
857-371-4638

SOURCE: Moderna, Inc.

 



General Mills Reports Fiscal 2023 Third-quarter Results and Raises Full-year Outlook

General Mills Reports Fiscal 2023 Third-quarter Results and Raises Full-year Outlook

  • Net sales increased 13 percent from the prior year to $5.1 billion; organic net sales1 were up 16 percent
  • Operating profit declined 10 percent to $730 million; adjusted operating profit was up 20 percent in constant currency
  • Diluted earnings per share (EPS) of $0.92 was down 15 percent from the prior year; adjusted diluted EPS of $0.97 was up 17 percent in constant currency
  • Company raises full-year fiscal 2023 outlook

¹ Please see Note 8 to the Consolidated Financial Statements below for reconciliation of this and other non-GAAP measures used in this release.

MINNEAPOLIS–(BUSINESS WIRE)–
General Mills, Inc. (NYSE: GIS) today reported results for its fiscal 2023 third quarter.

“We built on our positive momentum and delivered strong results in the third quarter, including broad-based growth across each of our segments,” said General Mills Chairman and Chief Executive Officer Jeff Harmening. “Our team continues to manage well through ongoing supply chain disruptions and volatility in the operating environment. Our brands are winning with consumers, and we plan to sustain this momentum by continuing to invest in brand building, innovation, and capabilities that will drive future growth. With strong year-to-date performance and good visibility to the fourth quarter, we are once again raising our fiscal 2023 outlook for our key financial measures.”

General Mills is executing its Accelerate strategy to drive sustainable, profitable growth and top-tier shareholder returns over the long term. The strategy focuses on four pillars to create competitive advantages and win: boldly building brands, relentlessly innovating, unleashing scale, and standing for good. The company is prioritizing its core markets, global platforms, and local gem brands that have the best prospects for profitable growth and is committed to reshaping its portfolio with strategic acquisitions and divestitures to further enhance its growth profile.

Third Quarter Results Summary

  • Net sales increased 13 percent to $5.1 billion, including a 2-point headwind from net divestiture and acquisition activity and 1 point of unfavorable foreign currency exchange. Organic net sales increased 16 percent, driven by positive organic net price realization and mix, with organic pound volume essentially matching year-ago levels.
  • Gross margin was up 160 basis points to 32.5 percent of net sales, driven by favorable net price realization and mix, partially offset by higher input costs and unfavorable mark-to-market effects. Adjusted gross margin was up 240 basis points to 33.8 percent of net sales, driven by favorable net price realization and mix and Holistic Margin Management (HMM) cost savings, partially offset by input cost inflation and higher other cost of goods sold.
  • Operating profit of $730 million was down 10 percent, reflecting higher selling, general, and administrative (SG&A) expenses and a lower net gain on divestitures, partially offset by higher gross profit dollars. Operating profit margin of 14.2 percent was down 380 basis points. Constant-currency adjusted operating profit increased 20 percent, driven by higher adjusted gross profit dollars, partially offset by higher adjusted SG&A expenses, including a double-digit increase in media investment. Adjusted operating profit margin increased 80 basis points to 15.7 percent.
  • Net earnings attributable to General Mills declined 16 percent to $553 million and diluted EPS was down 15 percent to $0.92, driven by lower operating profit, lower after-tax earnings from joint ventures, higher net interest expense, and lower benefit plan non-service income, partially offset by lower net shares outstanding. Adjusted diluted EPS of $0.97 increased 17 percent in constant currency, driven by higher adjusted operating profit and lower net shares outstanding, partially offset by lower after-tax earnings from joint ventures, higher net interest expense, a higher adjusted effective tax rate, and lower benefit plan non-service income.

Nine Month Results Summary

  • Net sales increased 7 percent to $15.1 billion, including a 4-point headwind from net divestiture and acquisition activity and 1 point of unfavorable foreign currency exchange. Organic net sales increased 12 percent, driven by positive organic net price realization and mix, partially offset by lower organic pound volume.
  • Gross margin was down 80 basis points to 32.0 percent of net sales, driven by higher input costs, unfavorable mark-to-market effects, and the impact of market index pricing on bakery flour, partially offset by favorable net price realization and mix. Adjusted gross margin was up 110 basis points to 33.9 percent of net sales, driven by favorable net price realization and mix, partially offset by higher input costs and the impact of market index pricing on bakery flour.
  • Operating profit of $2.6 billion was up 6 percent, driven by net gains on divestitures and higher gross profit dollars, partially offset by higher SG&A expenses and unfavorable net corporate investment activity.Operating profit margin of 17.4 percent essentially matched year-ago levels. Constant-currency adjusted operating profit increased 11 percent, driven by higher adjusted gross profit dollars, partially offset by higher adjusted SG&A expenses, including a double-digit increase in media investment. Adjusted operating profit margin increased 60 basis points to 17.0 percent.
  • Net earnings attributable to General Mills increased 5 percent to $2.0 billion and diluted EPS was up 7 percent to $3.28, primarily reflecting higher operating profit and lower net shares outstanding, partially offset by lower after-tax earnings from joint ventures and lower benefit plan non-service income. Adjusted diluted EPS of $3.18 was up 14 percent in constant currency, driven primarily by higher adjusted operating profit, a lower adjusted effective tax rate, and lower net shares outstanding, partially offset by lower after-tax earnings from joint ventures and lower benefit plan non-service income.

Notes on Comparability

Financial results in the first nine months of fiscal 2023 reflected the acquisition of Tyson Foods’ pet treat business in the first quarter of fiscal 2022; the divestiture of the European yogurt business in the third quarter of fiscal 2022; the divestiture of certain international dough businesses in the third and fourth quarters of fiscal 2022; the acquisition of the TNT Crust foodservice business in the first quarter of fiscal 2023; and the divestiture of the Helper main meals and Suddenly Salad side dishes business in the first quarter of fiscal 2023.

Nine-month results in fiscal 2023 also included the impact of a voluntary recall on certain international Häagen-Dazs ice cream products, which was a headwind to net sales and operating profit results in the International segment. Unallocated corporate items in the first nine months included an additional $26 million of charges related to product disposals associated with the ice cream recall that were excluded from adjusted operating profit results. The company does not expect a further material impact from the ice cream recall going forward.

Operating Segment Results

Note: Tables may not foot due to rounding.

 

Components of Fiscal 2023 Reported Net Sales Growth

Third Quarter

Volume

Price/Mix

Foreign

Exchange

Reported

Net Sales

North America Retail

(1) pt

17 pts

(1) pt

15%

Pet

6 pts

8 pts

14%

North America Foodservice

6 pts

20 pts

25%

International

(10) pts

11 pts

(4) pts

(3)%

Total

14 pts

(1) pt

13%

 

 

 

 

 

Nine Months

 

 

 

 

North America Retail

(5) pts

17 pts

12%

Pet

(2) pts

13 pts

10%

North America Foodservice

2 pts

21 pts

23%

International

(31) pts

15 pts

(5) pts

(21)%

Total

(8) pts

16 pts

(1) pt

7%

Components of Fiscal 2023 Organic Net Sales Growth

Third Quarter

Organic

Volume

Organic

Price/Mix

Organic

Net Sales

Foreign

Exchange

Acquisitions &

Divestitures

Reported

Net Sales

North America Retail

18 pts

18%

(1) pt

(3) pts

15%

Pet

6 pts

8 pts

14%

14%

North America Foodservice

1 pt

18 pts

19%

6 pts

25%

International

(4) pts

11 pts

8%

(4) pts

(6) pts

(3)%

Total

16 pts

16%

(1) pt

(2) pts

13%

 

 

 

 

 

 

 

Nine Months

 

 

 

 

 

 

North America Retail

(4) pts

18 pts

14%

(2) pts

12%

Pet

(3) pts

12 pts

9%

1 pt

10%

North America Foodservice

(1) pt

19 pts

18%

5 pts

23%

International

(6) pts

9 pts

3%

(5) pts

(19) pts

(21)%

Total

(3) pts

16 pts

12%

(1) pt

(4) pts

7%

Fiscal 2023 Segment Operating Profit Growth

Third Quarter

% Change as Reported

% Change in Constant Currency

North America Retail

29%

29%

Pet

(7)%

(7)%

North America Foodservice

134%

134%

International

18%

27%

Total

28%

28%

 

 

 

Nine Months

 

 

North America Retail

24%

24%

Pet

(13)%

(13)%

North America Foodservice

24%

24%

International

(39)%

(33)%

Total

15%

16%

North America Retail Segment

Third-quarter net sales for General Mills’ North America Retail segment increased 15 percent to $3.2 billion, driven by favorable net price realization and mix, partially offset by a 3-point headwind from divestitures and a 1-point headwind from unfavorable foreign currency exchange. Organic net sales increased 18 percent. Net sales increased 22 percent in U.S. Meals & Baking Solutions, 19 percent in U.S. Snacks, and 7 percent in U.S. Morning Foods. Constant-currency net sales were up 8 percent in Canada. Segment operating profit of $787 million was up 29 percent as reported and in constant currency, driven primarily by favorable net price realization and mix, partially offset by higher input costs and higher SG&A expenses, including a double-digit increase in media investment.

Through nine months, North America Retail segment net sales increased 12 percent to $9.6 billion, including a 2-point headwind from divestitures. Organic net sales were up 14 percent. Segment operating profit of $2.4 billion was up 24 percent as reported and in constant currency, driven primarily by favorable net price realization and mix, partially offset by higher input costs, lower volume, and higher SG&A expenses, including a double-digit increase in media investment.

Pet Segment

Third-quarter net sales for the Pet segment increased 14 percent to $646 million, driven by favorable net price realization and mix and increased pound volume. Organic net sales were also up 14 percent. Net sales performance represented an acceleration from second quarter results, driven by improved customer service, increased brand-building and other commercial activities, and a rebuild of retailer inventory. Segment operating profit of $103 million was down 7 percent, driven primarily by input cost inflation, increased costs related to capacity expansion and service improvement, and higher SG&A expenses, including a double-digit increase in media investment, partially offset by favorable net price realization and mix, HMM cost savings, and higher volume.

Through nine months, Pet segment net sales increased 10 percent to $1.8 billion, including a 1-point benefit from the pet treats acquisition. Organic net sales were up 9 percent. Retailer inventory was stable in the first nine months, with estimated all-channel retail sales up high-single digits. Segment operating profit was down 13 percent to $312 million, driven primarily by higher input costs, higher SG&A expenses, and lower volume, partially offset by favorable net price realization and mix.

North America Foodservice Segment

Third-quarter net sales for the North America Foodservice segment increased 25 percent to $548 million, driven primarily by favorable net price realization and mix, including a 1-point benefit from market index pricing on bakery flour. Net sales results also included a 6-point benefit from the TNT Crust acquisition. Organic net sales were up 19 percent. Segment operating profit increased 134 percent to $82 million, driven primarily by favorable net price realization and mix, partially offset by higher input costs.

Through nine months, North America Foodservice net sales increased 23 percent to $1.6 billion, including a 5-point benefit from the TNT Crust acquisition. Organic net sales were up 18 percent. Segment operating profit increased 24 percent to $218 million, driven primarily by favorable net price realization and mix, partially offset by higher input costs and higher SG&A expenses.

International Segment

Third-quarter net sales for the International segment were down 3 percent to $701 million, driven by lower pound volume, including a 6-point headwind from divestitures, and a 4-point headwind from foreign currency exchange, partially offset by favorable net price realization and mix. Organic net sales were up 8 percent, with broad-based growth across Europe & Australia, distributor markets, Brazil, and China. Segment operating profit of $42 million was up 18 percent as reported and up 27 percent in constant currency, driven by favorable net price realization and mix and lower SG&A expenses, partially offset by higher input costs and lower volume, including the impact of divestitures.

Through nine months, International net sales were down 21 percent to $2.0 billion, driven by lower pound volume, largely reflecting the impact of the yogurt and dough divestitures and the ice cream recall, and a 5-point headwind from foreign currency exchange, partially offset by favorable net price realization and mix. Organic net sales were up 3 percent. Segment operating profit of $95 million was down 39 percent as reported and down 33 percent in constant currency, driven by lower volume, including the impacts of the yogurt and dough divestitures and the ice cream recall, and higher input costs, partially offset by favorable net price realization and mix and lower SG&A expenses.

Joint Venture Summary

Third-quarter constant-currency net sales increased 2 percent for Cereal Partners Worldwide (CPW) and were up 1 percent for Häagen-Dazs Japan (HDJ). Combined after-tax earnings from joint ventures totaled $13 million compared to $30 million a year ago, driven primarily by higher input costs and unfavorable nonrecurring discrete tax items at CPW, partially offset by favorable net price realization and mix at CPW. Through nine months, after-tax earnings from joint ventures totaled $58 million compared to $92 million a year ago.

Other Income Statement Items

Unallocated corporate items totaled $296 million net expense in the third quarter of fiscal 2023, compared to $141 million net expense a year ago. Excluding mark-to-market valuation effects and other items affecting comparability, unallocated corporate items totaled $206 million net expense this year compared to $117 million net expense last year, driven primarily by higher compensation and benefits expense, corporate charitable contributions, and capability investments.

Restructuring, impairment, and other exit costs totaled $1 million in the third quarter of fiscal 2023 compared to $7 million a year ago (please see Note 4 below for more information on these charges). Benefit plan non-service income totaled $22 million in the third quarter compared to $27 million a year ago, driven primarily by an increase in interest cost, partially offset by lower amortization of losses.

Net interest expense of $98 million was up 14 percent, driven primarily by higher interest rates, partially offset by lower average long-term debt balances. The effective tax rate in the quarter was 16.6 percent compared to 16.3 percent last year (please see Note 7 below for more information on our effective tax rate). The adjusted effective tax rate was 21.6 percent compared to 21.0 percent a year ago.

Cash Flow Generation and Cash Returns

Cash provided by operating activities totaled $2.0 billion through nine months of fiscal 2023 compared to $2.2 billion a year ago, driven primarily by an increase in inventory and higher cash tax payments. Capital investments of $351 million essentially matched year-ago levels. Dividends paid increased 4 percent to $967 million. General Mills repurchased approximately 15 million shares of common stock through nine months of fiscal 2023 for a total of $1.2 billion compared to $550 million in share repurchases a year ago. Average diluted shares outstanding through nine months decreased 2 percent to 602 million.

Fiscal 2023 Outlook

General Mills continues to expect the largest factors impacting its performance in fiscal 2023 will be the economic health of consumers, the inflationary cost environment, and the frequency and severity of disruptions in the supply chain. For the full year, the company continues to expect input cost inflation of 14 to 15 percent of total cost of goods sold, HMM cost savings of 3 to 4 percent of cost of goods sold, moderately lower supply chain disruptions compared to the prior year, and increased investment in brand building and other growth-driving activities.

With stronger and more broad-based business momentum, the company is raising its outlook for fiscal 2023. The updated full-year financial targets are summarized below¹:

  • Organic net sales are now expected to increase 10 to 11 percent, compared to the previous expectation of approximately 10 percent growth.
  • Adjusted operating profit is now expected to increase 7 to 8 percent in constant currency, compared to the previous range of up 6 to 7 percent. Both the current and previous ranges include a 3-point net headwind from divestitures and acquisitions and an estimated 1-point headwind from the ice cream recall.
  • Adjusted diluted EPS is now expected to increase 8 to 9 percent in constant currency, compared to the previous range of up 7 to 8 percent. Both the current and previous ranges include a 3-point net headwind from divestitures and acquisitions and an estimated 1-point headwind from the ice cream recall.
  • Free cash flow conversion is still expected to be at least 90 percent of adjusted after-tax earnings.
  • The net impact of divestitures, acquisitions, and foreign currency exchange is expected to reduce full-year reported net sales growth by approximately 4.5 percent, and foreign currency exchange is expected to reduce adjusted operating profit and adjusted diluted EPS growth by approximately 1 percent.

¹ Financial targets are provided on a non-GAAP basis because certain information necessary to calculate comparable GAAP measures is not available. Please see Note 8 to the Consolidated Financial Statements below for discussion of the unavailable information.

General Mills will issue pre-recorded management remarks today, March 23, 2022, at approximately 6:30 a.m. Central time (7:30 a.m. Eastern time) and will hold a live, webcasted question and answer session beginning at 8:00 a.m. Central time (9:00 a.m. Eastern time). The pre-recorded remarks and the webcast will be made available at www.generalmills.com/investors.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on our current expectations and assumptions. These forward-looking statements, including the statements under the caption “Fiscal 2023 Outlook,” and statements made by Mr. Harmening, are subject to certain risks and uncertainties that could cause actual results to differ materially from the potential results discussed in the forward-looking statements. In particular, our predictions about future net sales and earnings could be affected by a variety of factors, including: the impact of the coronavirus (COVID-19) pandemic on our business, suppliers, consumers, customers, and employees; disruptions or inefficiencies in the supply chain, including any impact of the coronavirus (COVID-19) pandemic; competitive dynamics in the consumer foods industry and the markets for our products, including new product introductions, advertising activities, pricing actions, and promotional activities of our competitors; economic conditions, including changes in inflation rates, interest rates, tax rates, or the availability of capital; product development and innovation; consumer acceptance of new products and product improvements; consumer reaction to pricing actions and changes in promotion levels; acquisitions or dispositions of businesses or assets; changes in capital structure; changes in the legal and regulatory environment, including tax legislation, labeling and advertising regulations, and litigation; impairments in the carrying value of goodwill, other intangible assets, or other long-lived assets, or changes in the useful lives of other intangible assets; changes in accounting standards and the impact of critical accounting estimates; product quality and safety issues, including recalls and product liability; changes in consumer demand for our products; effectiveness of advertising, marketing, and promotional programs; changes in consumer behavior, trends, and preferences, including weight loss trends; consumer perception of health-related issues, including obesity; consolidation in the retail environment; changes in purchasing and inventory levels of significant customers; fluctuations in the cost and availability of supply chain resources, including raw materials, packaging, energy, and transportation; effectiveness of restructuring and cost saving initiatives; volatility in the market value of derivatives used to manage price risk for certain commodities; benefit plan expenses due to changes in plan asset values and discount rates used to determine plan liabilities; failure or breach of our information technology systems; foreign economic conditions, including currency rate fluctuations; and political unrest in foreign markets and economic uncertainty due to terrorism or war. The company undertakes no obligation to publicly revise any forward-looking statement to reflect any future events or circumstances.

# # #

Consolidated Statements of Earnings and Supplementary Information

GENERAL MILLS, INC. AND SUBSIDIARIES

(Unaudited) (In Millions, Except per Share Data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Quarter Ended

 

Nine-Month Period Ended

 

Feb. 26,

 

Feb. 27,

 

 

 

 

Feb. 26,

 

Feb. 27,

 

 

 

 

2023

 

2022

 

% Change

 

2023

 

2022

 

% Change

Net sales

$

5,125.9

 

 

$

4,537.7

 

 

13

 

%

 

$

15,064.2

 

 

$

14,101.6

 

 

7

 

%

Cost of sales

 

3,461.1

 

 

 

3,134.0

 

 

10

 

%

 

 

10,246.6

 

 

 

9,469.3

 

 

8

 

%

Selling, general, and administrative expenses

 

946.9

 

 

 

751.4

 

 

26

 

%

 

 

2,632.5

 

 

 

2,337.6

 

 

13

 

%

Divestitures gain, net

 

(13.7

)

 

 

(170.1

)

 

(92

)

%

 

 

(444.6

)

 

 

(170.1

)

 

161

 

%

Restructuring, impairment, and other exit

costs

 

1.4

 

 

 

7.1

 

 

(80

)

%

 

 

14.1

 

 

 

5.1

 

 

176

 

%

Operating profit

 

730.2

 

 

 

815.3

 

 

(10

)

%

 

 

2,615.6

 

 

 

2,459.7

 

 

6

 

%

Benefit plan non-service income

 

(21.6

)

 

 

(27.1

)

 

(20

)

%

 

 

(65.0

)

 

 

(84.4

)

 

(23

)

%

Interest, net

 

98.3

 

 

 

86.5

 

 

14

 

%

 

 

277.5

 

 

 

275.1

 

 

1

 

%

Earnings before income taxes and after-tax

earnings from joint ventures

 

653.5

 

 

 

755.9

 

 

(14

)

%

 

 

2,403.1

 

 

 

2,269.0

 

 

6

 

%

Income taxes

 

108.3

 

 

 

123.2

 

 

(12

)

%

 

 

471.5

 

 

 

451.8

 

 

4

 

%

After-tax earnings from joint ventures

 

12.7

 

 

 

29.9

 

 

(58

)

%

 

 

57.9

 

 

 

92.0

 

 

(37

)

%

Net earnings, including earnings attributable to

redeemable and noncontrolling interests

 

557.9

 

 

 

662.6

 

 

(16

)

%

 

 

1,989.5

 

 

 

1,909.2

 

 

4

 

%

Net earnings attributable to redeemable and

noncontrolling interests

 

4.8

 

 

 

2.3

 

 

109

 

%

 

 

10.5

 

 

 

24.7

 

 

(57

)

%

Net earnings attributable to General Mills

$

553.1

 

 

$

660.3

 

 

(16

)

%

 

$

1,979.0

 

 

$

1,884.5

 

 

5

 

%

Earnings per share – basic

$

0.94

 

 

$

1.09

 

 

(14

)

%

 

$

3.32

 

 

$

3.10

 

 

7

 

%

Earnings per share – diluted

$

0.92

 

 

$

1.08

 

 

(15

)

%

 

$

3.28

 

 

$

3.07

 

 

7

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Quarter Ended

 

 

Nine-Month Period Ended

 

 

Feb. 26,

 

Feb. 27,

 

Basis Pt

 

 

 

Feb. 26,

 

Feb. 27,

 

Basis Pt

 

Comparisons as a % of net sales:

 

2023

 

2022

 

Change

 

 

 

2023

 

2022

 

Change

 

Gross margin

 

32.5

%

 

 

30.9

%

 

160

 

 

 

 

32.0

%

 

 

32.8

%

 

(80

)

 

Selling, general, and administrative expenses

 

18.5

%

 

 

16.6

%

 

190

 

 

 

 

17.5

%

 

 

16.6

%

 

90

 

 

Operating profit

 

14.2

%

 

 

18.0

%

 

(380

)

 

 

 

17.4

%

 

 

17.4

%

 

 

 

Net earnings attributable to General Mills

 

10.8

%

 

 

14.6

%

 

(380

)

 

 

 

13.1

%

 

 

13.4

%

 

(30

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Quarter Ended

 

 

Nine-Month Period Ended

Comparisons as a % of net sales excluding

 

Feb. 26,

 

Feb. 27,

 

Basis Pt

 

 

 

Feb. 26,

 

Feb. 27,

 

Basis Pt

 

certain items affecting comparability (a):

 

2023

 

2022

 

Change

 

 

 

2023

 

2022

 

Change

 

Adjusted gross margin

 

33.8

%

 

 

31.4

%

 

240

 

 

 

 

33.9

%

 

 

32.8

%

 

110

 

 

Adjusted operating profit

 

15.7

%

 

 

14.9

%

 

80

 

 

 

 

17.0

%

 

 

16.4

%

 

60

 

 

Adjusted net earnings attributable to

General Mills

 

11.3

%

 

 

11.3

%

 

 

 

 

 

12.7

%

 

 

12.3

%

 

40

 

 

(a) See Note 8 for a reconciliation of these measures not defined by generally accepted accounting principles (GAAP).

 

See accompanying notes to consolidated financial statements.

Operating Segment Results and Supplementary Information

GENERAL MILLS, INC. AND SUBSIDIARIES

(Unaudited) (In Millions)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Quarter Ended

 

Nine-Month Period Ended

 

Feb. 26,

2023

 

Feb. 27,

2022

 

% Change

 

Feb. 26,

2023

 

 

Feb. 27,

2022

 

% Change

Net sales:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

North America Retail

$

3,232.0

 

 

$

2,811.9

 

 

15

 

%

 

$

9,593.9

 

 

$

8,567.1

 

 

12

 

%

International

 

700.6

 

 

 

721.0

 

 

(3

)

%

 

 

2,024.8

 

 

 

2,566.0

 

 

(21

)

%

Pet

 

645.5

 

 

 

567.7

 

 

14

 

%

 

 

1,818.3

 

 

 

1,649.1

 

 

10

 

%

North America Foodservice

 

547.8

 

 

 

437.1

 

 

25

 

%

 

 

1,627.2

 

 

 

1,319.4

 

 

23

 

%

Total

$

5,125.9

 

 

$

4,537.7

 

 

13

 

%

 

$

15,064.2

 

 

$

14,101.6

 

 

7

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating profit:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

North America Retail

$

786.9

 

 

$

611.5

 

 

29

 

%

 

$

2,401.8

 

 

$

1,935.5

 

 

24

 

%

International

 

42.4

 

 

 

35.9

 

 

18

 

%

 

 

95.0

 

 

 

155.9

 

 

(39

)

%

Pet

 

102.6

 

 

 

110.6

 

 

(7

)

%

 

 

312.3

 

 

 

357.3

 

 

(13

)

%

North America Foodservice

 

82.4

 

 

 

35.2

 

 

134

 

%

 

217.5

 

 

 

174.9

 

 

24

 

%

Total segment operating profit

$

1,014.3

 

 

$

793.2

 

 

28

 

%

 

$

3,026.6

 

 

$

2,623.6

 

 

15

 

%

Unallocated corporate items

 

296.4

 

 

 

140.9

 

 

110

 

%

 

 

841.5

 

 

 

328.9

 

 

156

 

%

Divestitures gain, net

 

(13.7

)

 

 

(170.1

)

 

(92

)

%

 

 

(444.6

)

 

 

(170.1

)

 

161

 

%

Restructuring, impairment, and other

exit costs

 

1.4

 

 

 

7.1

 

 

(80

)

%

 

 

14.1

 

 

 

5.1

 

 

176

 

%

Operating profit

$

730.2

 

 

$

815.3

 

 

(10

)

%

 

$

2,615.6

 

 

$

2,459.7

 

 

6

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Quarter Ended

 

 

Nine-Month Period Ended

 

 

Feb. 26,

2023

 

 

Feb. 27,

2022

 

Basis Pt

Change

 

 

 

Feb. 26,

2023

 

 

Feb. 27,

2022

 

Basis Pt

Change

 

Segment operating profit as a % of net sales:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

North America Retail

 

24.3

%

 

 

21.7

%

 

260

 

 

 

 

25.0

%

 

 

22.6

%

 

240

 

 

International

 

6.1

%

 

 

5.0

%

 

110

 

 

 

 

4.7

%

 

 

6.1

%

 

(140

)

 

Pet

 

15.9

%

 

 

19.5

%

 

(360

)

 

 

 

17.2

%

 

 

21.7

%

 

(450

)

 

North America Foodservice

 

15.0

%

 

 

8.1

%

 

690

 

 

 

 

13.4

%

 

 

13.3

%

 

10

 

 

Total segment operating profit

 

19.8

%

 

 

17.5

%

 

230

 

 

 

 

20.1

%

 

 

18.6

%

 

150

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

See accompanying notes to consolidated financial statements.

Consolidated Balance Sheets

GENERAL MILLS, INC. AND SUBSIDIARIES

(In Millions, Except Par Value)

 

 

 

 

 

 

 

 

 

 

Feb. 26, 2023

 

Feb. 27, 2022

 

May 29, 2022

 

(Unaudited)

 

(Unaudited)

 

 

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

$

618.7

 

 

$

844.4

 

 

$

569.4

 

Receivables

 

1,770.2

 

 

 

1,750.4

 

 

 

1,692.1

 

Inventories

 

2,083.3

 

 

 

1,710.0

 

 

 

1,867.3

 

Prepaid expenses and other current assets

 

643.8

 

 

 

723.8

 

 

 

802.1

 

Assets held for sale

 

 

 

 

 

 

 

158.9

 

Total current assets

 

5,116.0

 

 

 

5,028.6

 

 

 

5,089.8

 

Land, buildings, and equipment

 

3,353.6

 

 

 

3,287.9

 

 

 

3,393.8

 

Goodwill

 

14,487.8

 

 

 

14,546.7

 

 

 

14,378.5

 

Other intangible assets

 

6,968.0

 

 

 

7,010.9

 

 

 

6,999.9

 

Other assets

 

1,274.4

 

 

 

1,269.7

 

 

 

1,228.1

 

Total assets

$

31,199.8

 

 

$

31,143.8

 

 

$

31,090.1

 

LIABILITIES AND EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

$

3,868.2

 

 

$

3,474.6

 

 

$

3,982.3

 

Current portion of long-term debt

 

2,487.2

 

 

 

600.7

 

 

 

1,674.2

 

Notes payable

 

959.8

 

 

 

724.3

 

 

 

811.4

 

Other current liabilities

 

2,103.1

 

 

 

2,039.4

 

 

 

1,552.0

 

Total current liabilities

 

9,418.3

 

 

 

6,839.0

 

 

 

8,019.9

 

Long-term debt

 

8,140.2

 

 

 

10,944.7

 

 

 

9,134.8

 

Deferred income taxes

 

2,151.6

 

 

 

2,166.0

 

 

 

2,218.3

 

Other liabilities

 

1,006.0

 

 

 

1,118.4

 

 

 

929.1

 

Total liabilities

 

20,716.1

 

 

 

21,068.1

 

 

 

20,302.1

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Common stock, 754.6 shares issued, $0.10 par value

 

75.5

 

 

 

75.5

 

 

 

75.5

 

Additional paid-in capital

 

1,191.1

 

 

 

1,162.3

 

 

 

1,182.9

 

Retained earnings

 

19,226.5

 

 

 

17,713.1

 

 

 

18,532.6

 

Common stock in treasury, at cost, shares of 166.2, 152.4, and 155.7

 

(8,220.1

)

 

 

(7,015.3

)

 

 

(7,278.1

)

Accumulated other comprehensive loss

 

(2,038.5

)

 

 

(2,122.7

)

 

 

(1,970.5

)

Total stockholders’ equity

 

10,234.5

 

 

 

9,812.9

 

 

 

10,542.4

 

Noncontrolling interests

 

249.2

 

 

 

262.8

 

 

 

245.6

 

Total equity

 

10,483.7

 

 

 

10,075.7

 

 

 

10,788.0

 

Total liabilities and equity

$

31,199.8

 

 

$

31,143.8

 

 

$

31,090.1

 

 

 

 

 

 

 

 

 

 

Consolidated Statements of Cash Flows

GENERAL MILLS, INC. AND SUBSIDIARIES

(Unaudited) (In Millions)

 

Nine-Month Period Ended

 

Feb. 26, 2023

 

Feb. 27, 2022

Cash Flows – Operating Activities

 

 

 

 

 

Net earnings, including earnings attributable to redeemable and noncontrolling interests

$

1,989.5

 

 

$

1,909.2

 

Adjustments to reconcile net earnings to net cash provided by operating activities:

 

 

 

 

 

Depreciation and amortization

 

411.0

 

 

 

430.6

 

After-tax earnings from joint ventures

 

(57.9

)

 

 

(92.0

)

Distributions of earnings from joint ventures

 

36.6

 

 

 

49.0

 

Stock-based compensation

 

86.7

 

 

 

80.3

 

Deferred income taxes

 

(71.2

)

 

 

81.3

 

Pension and other postretirement benefit plan contributions

 

(20.2

)

 

 

(20.7

)

Pension and other postretirement benefit plan costs

 

(20.2

)

 

 

(10.6

)

Divestitures gain, net

 

(444.6

)

 

 

(170.1

)

Restructuring, impairment, and other exit costs

 

(14.6

)

 

 

(62.5

)

Changes in current assets and liabilities, excluding the effects of

acquisitions and divestitures

 

21.3

 

 

 

91.5

 

Other, net

 

110.6

 

 

 

(57.9

)

Net cash provided by operating activities

 

2,027.0

 

 

 

2,228.1

 

Cash Flows – Investing Activities

 

 

 

 

 

Purchases of land, buildings, and equipment

 

(351.3

)

 

 

(350.6

)

Acquisition, net of cash acquired

 

(251.5

)

 

 

(1,201.3

)

Proceeds from divestitures, net of cash divested

 

633.1

 

 

 

46.1

 

Investments in affiliates, net

 

(30.8

)

 

 

30.1

 

Proceeds from disposal of land, buildings, and equipment

 

0.8

 

 

 

1.6

 

Other, net

 

(6.4

)

 

 

12.3

 

Net cash used by investing activities

 

(6.1

)

 

 

(1,461.8

)

Cash Flows – Financing Activities

 

 

 

 

 

Change in notes payable

 

159.2

 

 

 

471.5

 

Issuance of long-term debt

 

501.8

 

 

 

1,935.2

 

Payment of long-term debt

 

(600.0

)

 

 

(2,278.2

)

Proceeds from common stock issued on exercised options

 

168.0

 

 

 

96.2

 

Purchases of common stock for treasury

 

(1,152.3

)

 

 

(550.5

)

Dividends paid

 

(967.4

)

 

 

(934.1

)

Distributions to noncontrolling and redeemable interest holders

 

(11.4

)

 

 

(110.8

)

Other, net

 

(53.5

)

 

 

(26.8

)

Net cash used by financing activities

 

(1,955.6

)

 

 

(1,397.5

)

Effect of exchange rate changes on cash and cash equivalents

 

(16.0

)

 

 

(29.6

)

Increase (decrease) in cash and cash equivalents

 

49.3

 

 

 

(660.8

)

Cash and cash equivalents – beginning of year

 

569.4

 

 

 

1,505.2

 

Cash and cash equivalents – end of period

$

618.7

 

 

$

844.4

 

Cash Flow from changes in current assets and liabilities, excluding the effects of

acquisitions and divestitures:

 

 

 

 

 

Receivables

$

(132.4

)

 

$

(214.5

)

Inventories

 

(237.0

)

 

 

102.5

 

Prepaid expenses and other current assets

 

151.5

 

 

 

41.5

 

Accounts payable

 

(41.6

)

 

 

(14.0

)

Other current liabilities

 

280.8

 

 

 

176.0

 

Changes in current assets and liabilities

$

21.3

 

 

$

91.5

 

See accompanying notes to consolidated financial statements.

 

 

 

 

 

GENERAL MILLS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

 

(1)

The accompanying Consolidated Financial Statements of General Mills, Inc. (we, us, our, General Mills, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States for annual and interim financial information. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal recurring nature.

 

 

(2)

In the third quarter of fiscal 2022, we completed a new organization structure to streamline our global operations. This global reorganization required us to reevaluate our operating segments. Under our new organization structure, our chief operating decision maker assesses performance and makes decisions about resources to be allocated to our operating segments as follows: North America Retail; International; Pet; and North America Foodservice. We have restated our net sales by segment and segment operating profit amounts to reflect our new operating segments. These segment changes had no effect on previously reported consolidated net sales, operating profit, net earnings attributable to General Mills, or earnings per share.

 

 

(3)

During the first quarter of fiscal 2023, we acquired TNT Crust, a manufacturer of high-quality frozen pizza crusts for regional and national pizza chains, foodservice distributors, and retail outlets, for a purchase price of $253 million. We financed the transaction with U.S. commercial paper. We consolidated the TNT Crust business into our Consolidated Balance Sheets and recorded goodwill of $154 million. The goodwill is included in the North America Foodservice segment and is not deductible for tax purposes. The pro forma effects of this acquisition were not material. The consolidated results of the TNT Crust business are reported in our North America Foodservice segment on a one-month lag.

 

 

During the first quarter of fiscal 2023, we completed the asset sale of our Helper main meals and Suddenly Salad side dishes business to Eagle Family Foods Group for $607 million and recorded a pre-tax gain of $442 million.

 

 

During the third quarter of fiscal 2022, we completed the sale of our interests in Yoplait SAS, Yoplait Marques SNC and Liberté Marques Sàrl to Sodiaal International (Sodiaal) in exchange for Sodiaal’s interest in our Canadian yogurt business, a modified agreement for the use of Yoplait and Liberté brands in the United States and Canada, and cash. We recorded a net pre-tax gain of $150 million on the sale of these businesses during the third quarter of fiscal 2022.

 

 

During the third quarter of fiscal 2022, we sold a European dough business and recorded a net pre-tax gain on sale of $21 million.

 

 

During the first quarter of fiscal 2022, we acquired Tyson Foods’ pet treats business for $1.2 billion in cash. We financed the transaction with a combination of cash on hand and short-term debt. We consolidated the pet treats business into our Consolidated Balance Sheets and recorded goodwill of $762 million, indefinite-lived intangible assets for the Nudges, Top Chews, and True Chews brands totaling $330 million in aggregate, and a finite-lived customer relationship asset of $40 million. The goodwill is included in the Pet segment and is deductible for tax purposes. The pro forma effects of this acquisition were not material.

 

(4)

In the nine-month period ended February 26, 2023, we did not undertake any new restructuring actions. We recorded $2 million of restructuring charges in the third quarter of fiscal 2023 and $16 million of restructuring charges in the nine-month period ended February 26, 2023, related to restructuring actions previously announced. We recorded $9 million of restructuring charges in the third quarter of fiscal 2022 and $8 million of restructuring charges in the nine-month period ended February 27, 2022, related to restructuring actions previously announced. We expect these actions to be completed by the end of fiscal 2024.

 

 

(5)

Unallocated corporate expense totaled $296 million in the third quarter of fiscal 2023, compared to $141 million in the same period in fiscal 2022. In the third quarter of fiscal 2023, we recorded a $67 million net increase in expense related to the mark-to-market valuation of certain commodity positions and grain inventories compared to a $20 million net increase in expense in the same period last year. We recorded $20 million of net losses related to valuation adjustments on certain corporate investments in the third quarter of fiscal 2023, compared to $11 million of net gains related to the sale of certain corporate investments and valuation adjustments in the third quarter of fiscal 2022. In addition, we recorded $1 million of integration costs primarily related to our acquisition of TNT Crust in the third quarter of fiscal 2023, compared to $4 million of integration costs related to our acquisition of Tyson Foods’ pet treats business in the third quarter of fiscal 2022. In the third quarter of fiscal 2022, we recorded $9 million of transaction costs related to the sale of our interests in Yoplait SAS, Yoplait Marques SNC, and Liberté Marques Sàrl and the sale of our European dough businesses. In addition, certain compensation and benefits expenses and charitable contributions increased in the third quarter of fiscal 2023, compared to the same period last year.

 

 

 

Unallocated corporate expense totaled $842 million in the nine-month period ended February 26, 2023, compared to $329 million in the same period last year. We recorded a $266 million net increase in expense related to the mark-to-market valuation of certain commodity positions and grain inventories in the nine-month period ended February 26, 2023, compared to a $16 million net decrease in expense in the same period last year. We recorded $82 million of net losses related to valuation adjustments and the sale of corporate investments in the nine-month period ended February 26, 2023, compared to $21 million of net gains in the same period last year. In the nine-month period ended February 26, 2023, we recorded a $26 million charge related to a voluntary recall on certain international Häagen-Dazs ice cream products. In addition, we recorded $5 million of integration costs primarily related to our acquisition of TNT Crust in the nine-month period ended February 26, 2023, compared to $20 million of integration costs related to our acquisition of Tyson Foods’ pet treats business in the nine-month period ended February 27, 2022. In the nine-month period ended February 26, 2023, we recorded $2 million of transaction costs primarily related to the sale of our Helper main meals and Suddenly Salad side dishes business compared to $57 million of transaction costs related to the sale of our interests in Yoplait SAS, Yoplait Marques SNC, Liberté Marques Sàrl and the sale of our European dough businesses. In addition, we recorded a $20 million recovery related to a Brazil indirect tax item and a $13 million insurance recovery in the nine-month period ended February 27, 2022. In addition, certain compensation and benefits expenses and charitable contributions increased in the nine-month period ended February 26, 2023, compared to the same period last year.

 

 

(6)

Basic and diluted earnings per share (EPS) were calculated as follows:

 

 

Quarter Ended

Nine-Month Period Ended

 

In Millions, Except per Share Data

Feb. 26, 2023

 

Feb. 27, 2022

Feb. 26, 2023

 

Feb. 27, 2022

 

Net earnings attributable to General Mills

$

553.1

 

$

660.3

$

1,979.0

 

$

1,884.5

 

Average number of common shares – basic EPS

 

592.5

 

 

606.8

 

596.2

 

 

608.6

 

Incremental share effect from: (a)

 

 

 

 

 

 

 

 

 

 

 

Stock options

 

3.7

 

 

2.9

 

3.6

 

 

2.4

 

Restricted stock units and performance share units

 

2.8

 

 

2.7

 

2.6

 

 

2.5

 

Average number of common shares – diluted EPS

 

599.0

 

 

612.4

 

602.4

 

 

613.5

 

Earnings per share – basic

$

0.94

 

$

1.09

$

3.32

 

$

3.10

 

Earnings per share – diluted

$

0.92

 

$

1.08

$

3.28

 

$

3.07

(a) Incremental shares from stock options, restricted stock units, and performance share units are computed by the treasury stock method.

(7)

The effective tax rate for the third quarter of fiscal 2023 was 16.6 percent compared to 16.3 percent for the third quarter of fiscal 2022. The 0.3 percentage point increase was primarily due to certain unfavorable nonrecurring discrete tax items, partially offset by favorable changes in earnings mix by jurisdiction in fiscal 2023. Our effective tax rate excluding certain items affecting comparability was 21.6 percent in the third quarter of fiscal 2023, compared to 21.0 percent in the same period last year (see the “Non-GAAP Measures” section below for a description of our use of measures not defined by GAAP). The 0.6 percentage point increase was primarily due to certain unfavorable nonrecurring discrete tax items, partially offset by favorable changes in earnings mix by jurisdiction in the third quarter of fiscal 2023.

 

The effective tax rate for the nine-month period ended February 26, 2023, was 19.6 percent compared to 19.9 percent in the nine-month period ended February 27, 2022. The 0.3 percentage point decrease was primarily due to certain nonrecurring discrete tax benefits and favorable changes in earnings mix by jurisdiction, partially offset by certain unfavorable tax components related to the divestitures incurred in the nine-month period ended February 26, 2023. Our effective tax rate excluding certain items affecting comparability was 20.8 percent in the nine-month period ended February 26, 2023, compared to 21.7 percent in the same period last year (see the “Non-GAAP Measures” section below for a description of our use of measures not defined by GAAP). The 0.9 percentage point decrease is primarily due to certain nonrecurring discrete tax benefits and favorable changes in earnings mix by jurisdiction in the nine-month period ended February 26, 2023.

 

(8)

We have included measures in this release that are not defined by GAAP. We believe that these measures provide useful information to investors, and include these measures in other communications to investors. For each of these non-GAAP financial measures, we are providing below a reconciliation of the differences between the non-GAAP measure and the most directly comparable GAAP measure, an explanation of why we believe the non-GAAP measure provides useful information to investors and any additional material purposes for which our management or Board of Directors uses the non-GAAP measure. These non-GAAP measures should be viewed in addition to, and not in lieu of, the comparable GAAP measure.

 

We provide organic net sales growth rates for our consolidated net sales and segment net sales. This measure is used in reporting to our Board of Directors and executive management and as a component of the Board of Directors’ measurement of our performance for incentive compensation purposes. We believe that organic net sales growth rates provide useful information to investors because they provide transparency to underlying performance in our net sales by excluding the effect that foreign currency exchange rate fluctuations, acquisitions, divestitures, and a 53rd fiscal week, when applicable, have on year-to-year comparability. A reconciliation of these measures to reported net sales growth rates, the relevant GAAP measures, are included in our Operating Segment Results above.

 

Certain measures in this release are presented excluding the impact of foreign currency exchange (constant-currency). To present this information, current period results for entities reporting in currencies other than United States dollars are translated into United States dollars at the average exchange rates in effect during the corresponding period of the prior fiscal year, rather than the actual average exchange rates in effect during the current fiscal year. Therefore, the foreign currency impact is equal to current year results in local currencies multiplied by the change in the average foreign currency exchange rate between the current fiscal period and the corresponding period of the prior fiscal year. We believe that these constant-currency measures provide useful information to investors because they provide transparency to underlying performance by excluding the effect that foreign currency exchange rate fluctuations have on period-to-period comparability given volatility in foreign currency exchange markets.

 

Our fiscal 2023 outlook for organic net sales growth, adjusted operating profit growth, adjusted diluted EPS growth, and free cash flow conversion are non-GAAP financial measures that exclude, or have otherwise been adjusted for, items impacting comparability, including the effect of foreign currency exchange rate fluctuations, acquisitions, divestitures, and a 53rd week, when applicable. We are not able to reconcile these forward-looking non-GAAP financial measures to their most directly comparable forward-looking GAAP financial measure without unreasonable efforts because we are unable to predict with a reasonable degree of certainty the actual impact of changes in foreign currency exchange rates or the timing of acquisitions and divestitures throughout fiscal 2023. The unavailable information could have a significant impact on our fiscal 2023 GAAP financial results.

 

For fiscal 2023, we currently expect: foreign currency exchange rates (based on a blend of forward and forecasted rates and hedge positions) and completed acquisitions and divestitures to reduce net sales growth by approximately 4.5 percent; foreign currency exchange rates to reduce adjusted operating profit and adjusted diluted EPS growth by approximately 1 percent; and restructuring charges and project-related costs, transaction and acquisition integration costs related to actions previously announced, and product disposal charges related to the ice cream recall to total approximately $55 million to $60 million.

Significant Items Impacting Comparability

Several measures below are presented on an adjusted basis. The adjustments are either items resulting from infrequently occurring events or items that, in management’s judgement, significantly affect the year-to-year assessment of operating results.

The following are descriptions of significant items impacting comparability of our results.

Divestitures gain, net

Net divestitures gain primarily related to the sale of our Helper main meals and Suddenly Salad side dishes business in fiscal 2023. Divestitures gain related to the sale of our interests in Yoplait SAS, Yoplait Marques SNC, and Liberté Marques Sàrl and the sale of a European dough business in fiscal 2022. Please see Note 3.

Mark-to-market effects

Net mark-to-market valuation of certain commodity positions recognized in unallocated corporate items. Please see Note 5.

Investment activity, net

Valuation adjustments and the loss on sale of certain corporate investments in fiscal 2023. Valuation adjustments and the gain on sale of certain corporate investments in fiscal 2022. Please see Note 5.

Product recall

Voluntary recall costs recorded in fiscal 2023 related to certain international Häagen-Dazs ice cream products. Please see Note 5.

Restructuring charges

Restructuring charges for previously announced restructuring actions recorded in fiscal 2023 and fiscal 2022. Please see Note 4.

Acquisition integration costs

Integration costs primarily resulting from the acquisition of TNT Crust in fiscal 2023. Integration costs resulting from the acquisition of Tyson Foods’ pet treats business in fiscal 2022. Please see Note 3.

Transaction costs

Transaction costs primarily related to the sale of our Helper main meals and Suddenly Salad side dishes business in fiscal 2023. Transaction costs related to the sale of our interests in Yoplait SAS, Yoplait Marques SNC, and Liberté Marques Sàrl and the sale of our European dough businesses in fiscal 2022. Please see Note 3.

Non-income tax recovery

Recovery related to a Brazil indirect tax item recorded in fiscal 2022.

CPW restructuring charges

CPW restructuring charges related to previously announced restructuring actions.

Adjusted Operating Profit Growth on a Constant-currency Basis

This measure is used in reporting to our Board of Directors and executive management and as a component of the measurement of our performance for incentive compensation purposes. We believe that this measure provides useful information to investors because it is the operating profit measure we use to evaluate operating profit performance on a comparable year-to-year basis. The measure is evaluated on a constant-currency basis by excluding the effect that foreign currency exchange rate fluctuations have on year-to-year comparability given the volatility in foreign currency exchange rates.

Our adjusted operating profit growth on a constant-currency basis is calculated as follows:

 

Quarter Ended

 

Nine-Month Period Ended

 

Feb. 26, 2023

 

Feb. 27, 2022

Change

 

Feb. 26, 2023

 

Feb. 27, 2022

Change

Operating profit as reported

$

730.2

 

 

$

815.3

 

(10

)

%

 

$

2,615.6

 

 

$

2,459.7

 

6

 

%

Divestitures gain, net

 

(13.7

)

 

 

(170.1

)

 

 

 

 

(444.6

)

 

 

(170.1

)

 

 

Mark-to-market effects

 

66.6

 

 

 

20.0

 

 

 

 

 

266.4

 

 

 

(16.2

)

 

 

Investment activity, net

 

20.1

 

 

 

(11.1

)

 

 

 

 

82.1

 

 

 

(20.9

)

 

 

Product recall

 

1.1

 

 

 

 

 

 

 

 

25.5

 

 

 

 

 

 

Restructuring charges

 

2.1

 

 

 

9.3

 

 

 

 

 

16.0

 

 

 

7.9

 

 

 

Acquisition integration costs

 

0.7

 

 

 

4.3

 

 

 

 

 

5.0

 

 

 

20.2

 

 

 

Transaction costs

 

 

 

 

8.6

 

 

 

 

 

2.0

 

 

 

56.8

 

 

 

Non-income tax recovery

 

 

 

 

0.2

 

 

 

 

 

 

 

 

(20.4

)

 

 

Adjusted operating profit

$

807.0

 

 

$

676.5

 

19

 

%

 

$

2,567.9

 

 

$

2,317.0

 

11

 

%

Foreign currency exchange impact

 

 

 

 

 

(1

)

pt

 

 

 

 

 

(1

)

pt

Adjusted operating profit growth,

on a constant-currency basis

 

 

 

 

 

20

 

%

 

 

 

 

 

 

11

 

%

Note: Table may not foot due to rounding.

For more information on the reconciling items, please refer to the Significant Items Impacting Comparability section above.

Adjusted Diluted EPS and Related Constant-currency Growth Rates

This measure is used in reporting to our Board of Directors and executive management. We believe that this measure provides useful information to investors because it is the profitability measure we use to evaluate earnings performance on a comparable year-to-year basis.

The reconciliation of our GAAP measure, diluted EPS, to adjusted diluted EPS and the related constant-currency growth rates follows:

 

Quarter Ended

 

Nine-Month Period Ended

Per Share Data

Feb. 26, 2023

 

Feb. 27, 2022

Change

 

Feb. 26, 2023

 

Feb. 27, 2022

Change

Diluted earnings per share, as reported

$

0.92

 

 

$

1.08

 

(15

)

%

 

$

3.28

 

 

$

3.07

 

7

 

%

Divestitures gain, net

 

(0.08

)

 

 

(0.28

)

 

 

 

 

(0.62

)

 

 

(0.28

)

 

 

Mark-to-market effects

 

0.09

 

 

 

0.03

 

 

 

 

 

0.34

 

 

 

(0.02

)

 

 

Investment activity, net

 

0.03

 

 

 

(0.01

)

 

 

 

 

0.11

 

 

 

(0.03

)

 

 

Product recall

 

 

 

 

 

 

 

 

 

0.03

 

 

 

 

 

 

Restructuring charges

 

 

 

 

0.02

 

 

 

 

 

0.02

 

 

 

0.01

 

 

 

Acquisition integration costs

 

 

 

 

0.01

 

 

 

 

 

0.01

 

 

 

0.03

 

 

 

Transaction costs

 

 

 

 

0.01

 

 

 

 

 

 

 

 

0.07

 

 

 

Non-income tax recovery

 

 

 

 

 

 

 

 

 

 

 

 

(0.02

)

 

 

Adjusted diluted earnings per share

$

0.97

 

 

$

0.84

 

15

 

%

 

$

3.18

 

 

$

2.82

 

13

 

%

Foreign currency exchange impact

 

 

 

 

 

(1

)

pt

 

 

 

 

 

(1

)

pt

Adjusted diluted earnings per share

growth, on a constant-currency basis

 

 

 

 

 

17

 

%

 

 

 

 

 

 

14

 

%

Note: Table may not foot due to rounding.

For more information on the reconciling items, please refer to the Significant Items Impacting Comparability section above.

See our reconciliation below of the effective income tax rate as reported to the adjusted effective income tax rate for the tax impact of each item affecting comparability.

Adjusted Earnings Comparisons as a Percent of Net Sales

We believe that these measures provide useful information to investors because they are important for assessing our adjusted earnings comparisons as a percent of net sales on a comparable year-to-year basis.

Our adjusted earnings comparisons as a percent of net sales are calculated as follows:

 

Quarter Ended

In Millions

Feb. 26, 2023

 

Feb. 27, 2022

Comparisons as a % of Net Sales

Value

 

Percent of

Net Sales

 

Value

 

Percent of

Net Sales

Gross margin as reported (a)

$

1,664.8

 

 

32.5

 

%

 

$

1,403.7

 

 

30.9

 

%

Mark-to-market effects

 

66.6

 

 

1.3

 

%

 

 

20.0

 

 

0.4

 

%

Product recall

 

0.8

 

 

 

%

 

 

 

 

 

%

Restructuring charges

 

0.7

 

 

 

%

 

 

2.2

 

 

 

%

Adjusted gross margin

$

1,732.8

 

 

33.8

 

%

 

$

1,425.9

 

 

31.4

 

%

 

 

 

 

 

 

 

 

 

 

 

 

Operating profit as reported

$

730.2

 

 

14.2

 

%

 

$

815.3

 

 

18.0

 

%

Divestitures gain, net

 

(13.7

)

 

(0.3

)

%

 

 

(170.1

)

 

(3.7

)

%

Mark-to-market effects

 

66.6

 

 

1.3

 

%

 

 

20.0

 

 

0.4

 

%

Investment activity, net

 

20.1

 

 

0.4

 

%

 

 

(11.1

)

 

(0.2

)

%

Product recall

 

1.1

 

 

 

%

 

 

 

 

 

%

Restructuring charges

 

2.1

 

 

 

%

 

 

9.3

 

 

0.2

 

%

Acquisition integration costs

 

0.7

 

 

 

%

 

 

4.3

 

 

0.1

 

%

Transaction costs

 

 

 

 

%

 

 

8.6

 

 

0.2

 

%

Non-income tax recovery

 

 

 

 

%

 

 

0.2

 

 

 

%

Adjusted operating profit

$

807.0

 

 

15.7

 

%

 

$

676.5

 

 

14.9

 

%

 

 

 

 

 

 

 

 

 

 

 

 

Net earnings attributable to General Mills as reported

$

553.1

 

 

10.8

 

%

 

$

660.3

 

 

14.6

 

%

Divestitures gain, net of tax (b)

 

(42.4

)

 

(0.8

)

%

 

 

(170.5

)

 

(3.8

)

%

Mark-to-market effects, net of tax (b)

 

51.3

 

 

1.0

 

%

 

 

15.3

 

 

0.3

 

%

Investment activity, net, net of tax (b)

 

15.6

 

 

0.3

 

%

 

 

(10.9

)

 

(0.2

)

%

Product recall, net of tax (b)

 

0.8

 

 

 

%

 

 

 

 

 

%

Restructuring charges, net of tax (b)

 

1.4

 

 

 

%

 

 

7.6

 

 

0.2

 

%

Acquisition integration costs, net of tax (b)

 

0.6

 

 

 

%

 

 

3.3

 

 

0.1

 

%

Transaction costs, net of tax (b)

 

 

 

 

%

 

 

9.8

 

 

0.2

 

%

CPW restructuring charges

 

0.9

 

 

 

%

 

 

(1.2

)

 

 

%

Non-income tax recovery, net of tax (b)

 

 

 

 

%

 

 

0.2

 

 

 

%

Adjusted net earnings attributable to General Mills

$

581.3

 

 

11.3

 

%

 

$

513.9

 

 

11.3

 

%

Note: Table may not foot due to rounding.

For more information on the reconciling items, please refer to the Significant Items Impacting Comparability section above.
(a) Net sales less cost of sales.
(b) See reconciliation of adjusted effective income tax rate below for tax impact of each adjustment.

 

Nine-Month Period Ended

In Millions

Feb. 26, 2023

 

Feb. 27, 2022

Comparisons as a % of Net Sales

Value

 

Percent of

Net Sales

 

Value

 

Percent of

Net Sales

Gross margin as reported (a)

$

4,817.6

 

 

32.0

 

%

 

$

4,632.3

 

 

32.8

 

%

Mark-to-market effects

 

266.4

 

 

1.8

 

%

 

 

(16.2

)

 

(0.1

)

%

Product recall

 

24.8

 

 

0.2

 

%

 

 

 

 

 

%

Restructuring charges

 

1.9

 

 

 

%

 

 

2.8

 

 

 

%

Acquisition integration costs

 

 

 

 

%

 

 

0.1

 

 

 

%

Transaction costs

 

 

 

 

%

 

 

0.8

 

 

 

%

Adjusted gross margin

$

5,110.6

 

 

33.9

 

%

 

$

4,619.8

 

 

32.8

 

%

 

 

 

 

 

 

 

 

 

 

 

 

Operating profit as reported

$

2,615.6

 

 

17.4

 

%

 

$

2,459.7

 

 

17.4

 

%

Divestitures gain, net

 

(444.6

)

 

(3.0

)

%

 

 

(170.1

)

 

(1.2

)

%

Mark-to-market effects

 

266.4

 

 

1.8

 

%

 

 

(16.2

)

 

(0.1

)

%

Investment activity, net

 

82.1

 

 

0.5

 

%

 

 

(20.9

)

 

(0.1

)

%

Product recall

 

25.5

 

 

0.2

 

%

 

 

 

 

 

%

Restructuring charges

 

16.0

 

 

0.1

 

%

 

 

7.9

 

 

0.1

 

%

Acquisition integration costs

 

5.0

 

 

 

%

 

 

20.2

 

 

0.1

 

%

Transaction costs

 

2.0

 

 

 

%

 

 

56.8

 

 

0.4

 

%

Non-income tax recovery

 

 

 

 

%

 

 

(20.4

)

 

(0.1

)

%

Adjusted operating profit

$

2,567.9

 

 

17.0

 

%

 

$

2,317.0

 

 

16.4

 

%

 

 

 

 

 

 

 

 

 

 

 

 

Net earnings attributable to General Mills as reported

$

1,979.0

 

 

13.1

 

%

 

$

1,884.5

 

 

13.4

 

%

Divestitures gain, net, net of tax (b)

 

(371.4

)

 

(2.5

)

%

 

 

(170.5

)

 

(1.2

)

%

Mark-to-market effects, net of tax (b)

 

205.1

 

 

1.4

 

%

 

 

(12.5

)

 

(0.1

)

%

Investment activity, net, net of tax (b)

 

64.1

 

 

0.4

 

%

 

 

(21.2

)

 

(0.2

)

%

Product recall, net of tax (b)

 

19.6

 

 

0.1

 

%

 

 

 

 

 

%

Restructuring charges, net of tax (b)

 

11.5

 

 

0.1

 

%

 

 

4.3

 

 

 

%

Acquisition integration costs, net of tax (b)

 

3.9

 

 

 

%

 

 

15.6

 

 

0.1

 

%

Transaction costs, net of tax (b)

 

1.4

 

 

 

%

 

 

44.9

 

 

0.3

 

%

CPW restructuring charges

 

1.0

 

 

 

%

 

 

(1.1

)

 

 

%

Non-income tax recovery, net of tax (b)

 

 

 

 

%

 

 

(13.4

)

 

(0.1

)

%

Adjusted net earnings attributable to General Mills

$

1,914.2

 

 

12.7

 

%

 

$

1,730.6

 

 

12.3

 

%

Note: Table may not foot due to rounding.

For more information on the reconciling items, please refer to the Significant Items Impacting Comparability section above.
(a) Net sales less cost of sales.
(b) See reconciliation of adjusted effective income tax rate below for tax impact of each adjustment.

Constant-currency Segment Operating Profit Growth Rates

We believe that this measure provides useful information to investors because it provides transparency to underlying performance of our segments by excluding the effect that foreign currency exchange rate fluctuations have on year-to-year comparability given volatility in foreign currency exchange markets.

Our segments’ operating profit growth rates on a constant-currency basis are calculated as follows:

 

 

Quarter Ended Feb. 26, 2023

 

 

Percentage Change in

Operating Profit as Reported

Impact of Foreign Currency

Exchange

Percentage Change in Operating Profit on Constant-Currency Basis

North America Retail

 

29

 

%

Flat

 

29

 

%

International

 

18

 

%

(8)

pts

27

 

%

Pet

 

(7

)

%

Flat

 

(7

)

%

North America Foodservice

 

134

 

%

Flat

 

134

 

%

Total segment operating profit

 

28

 

%

(1)

pt

28

 

%

 

 

 

 

Nine-Month Period Ended Feb. 26, 2023

 

 

Percentage Change in

Operating Profit

as Reported

Impact of Foreign

Currency Exchange

Percentage Change in

Operating Profit on

Constant-Currency Basis

North America Retail

 

24

 

%

Flat

 

24

 

%

International

 

(39

)

%

(6)

pts

(33

)

%

Pet

 

(13

)

%

Flat

 

(13

)

%

North America Foodservice

 

24

 

%

Flat

 

24

 

%

Total segment operating profit

 

15

 

%

(1)

pt

16

 

%

Note: Tables may not foot due to rounding.

 

Net Sales Growth Rates for Our Canada Operating Unit on a Constant-currency Basis

We believe that this measure of our Canada operating unit net sales provides useful information to investors because it provides transparency to underlying performance of our Canada operating unit within our North America Retail segment by excluding the effect that foreign currency exchange rate fluctuations have on year-to-year comparability given volatility in foreign currency exchange markets.

Net sales growth rates for our Canada operating unit on a constant-currency basis are calculated as follows:

 

 

Percentage Change in

Net Sales

as Reported

Impact of Foreign

Currency

Exchange

Percentage Change in

Net Sales on Constant-

Currency Basis

Quarter Ended Feb. 26, 2023

 

2

%

(6)

pts

8

%

Nine-Month Period Ended Feb. 26, 2023

 

1

%

(6)

pts

6

%

Note: Table may not foot due to rounding.

Adjusted Effective Income Tax Rate

We believe this measure provides useful information to investors because it presents the adjusted effective income tax rate on a comparable year-to-year basis.

Adjusted effective income tax rates are calculated as follows:

 

Quarter Ended

 

Nine-Month Period Ended

 

Feb. 26, 2023

 

Feb. 27, 2022

 

Feb. 26, 2023

 

Feb. 27, 2022

In Millions

(Except Per Share Data)

Pretax

Earnings (a)

Income

Taxes

 

Pretax

Earnings (a)

Income

Taxes

 

Pretax

Earnings

(a)

Income

Taxes

 

Pretax

Earnings

(a)

Income

Taxes

As reported

$

653.5

 

$

108.3

 

 

$

755.9

 

$

123.2

 

 

$

2,403.1

 

$

471.5

 

 

$

2,269.0

 

$

451.8

 

Divestitures gain, net

 

(13.7

)

 

28.7

 

 

 

(170.1

)

 

0.4

 

 

 

(444.6

)

 

(73.2

)

 

 

(170.1

)

 

0.4

 

Mark-to-market effects

 

66.6

 

 

15.3

 

 

 

20.0

 

 

4.6

 

 

 

266.4

 

 

61.3

 

 

 

(16.2

)

 

(3.7

)

Investment activity, net

 

20.1

 

 

4.5

 

 

 

(11.1

)

 

(0.2

)

 

 

82.1

 

 

18.0

 

 

 

(20.9

)

 

0.3

 

Product recall

 

1.1

 

 

0.3

 

 

 

 

 

 

 

 

25.5

 

 

5.9

 

 

 

 

 

 

Restructuring charges

 

2.1

 

 

0.7

 

 

 

9.3

 

 

1.7

 

 

 

16.0

 

 

4.5

 

 

 

7.9

 

 

3.6

 

Acquisition integration costs

 

0.7

 

 

0.1

 

 

 

4.3

 

 

1.0

 

 

 

5.0

 

 

1.1

 

 

 

20.2

 

 

4.6

 

Transaction costs

 

 

 

 

 

 

8.6

 

 

(1.2

)

 

 

2.0

 

 

0.6

 

 

 

56.8

 

 

11.2

 

Non-income tax recovery

 

 

 

 

 

 

0.2

 

 

0.1

 

 

 

 

 

 

 

 

(20.4

)

 

(6.9

)

As adjusted

$

730.3

 

$

157.8

 

 

$

617.1

 

$

129.5

 

 

$

2,355.4

 

$

489.6

 

 

$

2,126.3

 

$

461.3

 

Effective tax rate:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As reported

 

 

 

16.6

%

 

 

 

 

16.3

%

 

 

 

 

19.6

%

 

 

 

 

19.9

%

As adjusted

 

 

 

21.6

%

 

 

 

 

21.0

%

 

 

 

 

20.8

%

 

 

 

 

21.7

%

Sum of adjustment to

income taxes

 

 

$

49.5

 

 

 

 

$

6.4

 

 

 

 

$

18.1

 

 

 

 

$

9.5

 

Average number of common

shares – diluted EPS

 

 

 

599.0

 

 

 

 

 

612.4

 

 

 

 

 

602.4

 

 

 

 

 

613.5

 

Impact of income tax adjustments

on adjusted diluted EPS

 

 

$

(0.08

)

 

 

 

$

(0.01

)

 

 

 

$

(0.03

)

 

 

 

$

(0.02

)

Note: Table may not foot due to rounding.

(a) Earnings before income taxes and after-tax earnings from joint ventures.
For more information on the reconciling items, please refer to the Significant Items Impacting Comparability section above.

 

(Investors) Jeff Siemon: +1-763-764-2301

(Media) Chelcy Walker: +1-763-764-6364

KEYWORDS: United States North America Minnesota

INDUSTRY KEYWORDS: Marketing Advertising Retail Communications Blogging Food/Beverage

MEDIA:

Logo
Logo

Vontier Hosts 2023 Investor Day; Reaffirms 2023 Guidance and Introduces Long-term Financial Targets

Vontier Hosts 2023 Investor Day; Reaffirms 2023 Guidance and Introduces Long-term Financial Targets

RALEIGH, N.C.–(BUSINESS WIRE)–
Vontier Corporation (NYSE: VNT), a leading global provider of critical technologies and solutions to connect, manage and scale the mobility ecosystem, will hold its first Investor Day, today, March 23, 2023, at 8:30 a.m. ET to present an updated view of Vontier’s strategic & capital allocation priorities, growth strategy, and financial outlook.

“Vontier has unparalleled portfolio breadth and depth across the mobility ecosystem. We believe we are the only company capable of providing a full suite of hardware and software solutions to connect, manage, and scale assets across this $30 billion addressable market,” said Mark Morelli, President and CEO.

During today’s investor day event, the Vontier management team will discuss how the Company’s Connected Mobility Strategy is driving profitable growth and success across the mobility ecosystem in 2023 and beyond, as each business unit continues to scale and drive innovation to deliver significant value.

Vontier will affirm its 2023 outlook and introduce longer-term financial targets (2024 to 2026), including:

  • +4-6% Organic Revenue growth through 2026
  • 150+ basis points cumulative Adjusted Operating Profit Margin expansion through 2026
  • Double-digit Adjusted Diluted EPS growth CAGR
  • ~100% Adjusted Free Cash Flow Conversion

Morelli continued, “Vontier’s growth outlook and expanding cash flows are propelled by both leading market positions in connected automation and multi-energy fueling and robust secular tailwinds sweeping the mobility ecosystem. Our entire team is energized by our Connected Mobility Strategy and our ability to enable the way the world moves for years to come.”

Webcast Information

A more detailed agenda, presentations, and a live webcast will be available on the day of the event on the Company’s website at investor.vontier.com.

Investors and other interested stakeholders may register for Vontier’s 2023 Investor Day webcast here.

A replay of the webcast will be available shortly after the event concludes.

ABOUT VONTIER

Vontier (NYSE: VNT) is a global industrial technology company at the forefront of solving next-gen mobility challenges. Guided by the Vontier Business System and an unwavering commitment to our customers, Vontier delivers smart, sustainable solutions for the road ahead. To learn more, visit www.vontier.com.

NON-GAAP FINANCIAL MEASURES

This release references “organic revenue growth,” “adjusted operating profit margin,” “adjusted diluted EPS,” and “adjusted free cash flow conversion,” which are non-GAAP financial measures. A reconciliation of each of the projected organic revenue growth, adjusted operating profit margin, adjusted diluted EPS, and adjusted free cash flow conversion, which are forward-looking non-GAAP financial measures, to the most directly comparable GAAP financial measure, is not provided because the company is unable to provide such reconciliation without unreasonable effort. The inability to provide each reconciliation is due to the unpredictability of the amounts and timing of events affecting the items we exclude from the non-GAAP measure.

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements within the meaning of the federal securities laws. These statements include but are not limited to statements regarding Vontier Corporation’s (the “Company’s”) business and acquisition opportunities and anticipated earnings, and any other statements identified by their use of words like “anticipate,” “expect,” “believe,” “outlook,” “guidance,” or “will” or other words of similar meaning. There are a number of important risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These risks and uncertainties include, among other things, the effect of the COVID-19 pandemic on our global operations, deterioration of or instability in the economy, the markets we serve, international trade policies and the financial markets, contractions or lower growth rates and cyclicality of markets we serve, competition, changes in industry standards and governmental regulations that may adversely impact demand for our products or our costs, our ability to successfully identify, consummate, integrate and realize the anticipated value of appropriate acquisitions and successfully complete divestitures and other dispositions, our ability to develop and successfully market new products, software, and services and expand into new markets, the potential for improper conduct by our employees, agents or business partners, impact of divestitures, contingent liabilities relating to acquisitions and divestitures, impact of changes to tax laws, our compliance with applicable laws and regulations and changes in applicable laws and regulations, risks relating to international economic, political, war or hostility, legal, compliance and business factors, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, the impact of our debt obligations on our operations, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, our ability to adequately protect our intellectual property rights, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, our relationships with and the performance of our channel partners, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole sources of supply, security breaches or other disruptions of our information technology systems, adverse effects of restructuring activities, impact of changes to U.S. GAAP, labor matters, and disruptions relating to man-made and natural disasters. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our Annual Report on Form 10-K for the year ended December 31, 2022. These forward-looking statements represent Vontier’s beliefs and assumptions only as of the date of this release and Vontier does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

Ryan Edelman

Vice President, Investor Relations

Vontier Corporation

+1 (984) 238-1929

[email protected]

KEYWORDS: North Carolina United States North America

INDUSTRY KEYWORDS: Technology Automotive Transportation Travel Machinery Other Energy Public Transport Vehicle Technology IOT (Internet of Things) Engineering Energy Transport Other Technology Manufacturing Software Hardware EV/Electric Vehicles

MEDIA:

Logo
Logo

NovaBay Pharmaceuticals to Hold 2022 Fourth Quarter and Full Year Conference Call on March 30, 2023

NovaBay Pharmaceuticals to Hold 2022 Fourth Quarter and Full Year Conference Call on March 30, 2023

EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and 12 months ended December 31, 2022 after market close on Thursday, March 30, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.

Date/Time:

Thursday, March 30, 4:30 p.m. ET / 1:30 p.m. PT

 

 

 

 

Pre-Registration:

Participants can pre-register for the conference call here:

 

 

Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

 

 

 

 

Dial In:

Those who choose not to pre-register can access the live conference call by dialing the following and requesting the NovaBay Pharmaceuticals call:

 

 

866-777-2509 from within the U.S.

 

 

412-317-5413 from outside the U.S.

 

The live webcast of the conference call also will be available at https://investors.novabay.com/events/. A replay of the call will be available beginning two hours after its completion through April 20, 2023 by dialing 877-344-7529 from within the U.S., 855-669-9658 from Canada or 412-317-0088 from outside the U.S., and entering conference ID 6368470. The webcast will also be archived here.

About NovaBay Pharmaceuticals, Inc:

NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare and skincare products. NovaBay’s leading product, Avenova® Antimicrobial Lid & Lash Solution, is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is also available directly to eyecare consumers through online distribution channels such as Amazon. DERMAdoctor® offers more than 30 OTC dermatologist-developed skincare products through the DERMAdoctor website, well-known traditional and digital beauty retailers, and international distributors. NovaBay also manufactures and sells effective, yet gentle and non-irritating wound care products. The PhaseOne® brand is distributed through commercial partners in the U.S. for professional use only, and the NeutroPhase® brand is distributed in China by Pioneer Pharma (Hong Kong) Company Ltd.

Socialize and Stay Informed on NovaBays Progress

Like us on Facebook

Follow us on Twitter

Connect with NovaBay on LinkedIn

Visit NovaBay’s Website

Avenova Purchasing Information

For NovaBay Avenova purchasing information:

Please call 800-890-0329 or email [email protected]

Avenova.com

DERMAdoctor Purchasing Information

For DERMAdoctor purchasing information:

Please call 877-337-6237 or email [email protected]

DERMAdoctor.com

NovaBay Contact

Justin Hall

Chief Executive Officer and General Counsel

510-899-8800

[email protected]

Investor Contact

LHA Investor Relations

Jody Cain

310-691-7100

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Medical Supplies Health Other Science General Health Science Pharmaceutical Optical

MEDIA:

Castellum, Inc. Announces Closing of GTMR Acquisition

BETHESDA, Md., March 23, 2023 (GLOBE NEWSWIRE) — Castellum, Inc. (NYSE-American: CTM), a cybersecurity and electronic warfare services company focused on the federal government, announces that it has closed its previously announced acquisition of Global Technologies Management Resources, Inc. (“GTMR”), a $10 million revenue government contractor based in Hollywood, Maryland near Naval Air Station Patuxent River.

The transaction is immediately accretive on a revenue per share, recurring cash operating profit per share (a non-GAAP measure), and net income per share basis to Castellum. Pro forma for the acquisition, Castellum’s revenue run rate now exceeds $50 million. As a significant transaction under SEC Rule 3-05 of Regulation S-X, an audit of GTMR’s 2022 financials is being done and is expected to be completed within 60 days. The transaction was structured to be a “tax-free” reorganization under Section 368 of the Internal Revenue Code with just over 80% of the consideration in the form of Castellum restricted common stock. Additional details will be available on Form 8-K which Castellum will be filing in the upcoming days at www.sec.gov.

“We are thrilled to announce the closing of the GTMR acquisition,” said Mark Fuller, President and CEO of Castellum. “In addition to adding significant new capability to Castellum, strengthening our presence at Pax River, and being immediately accretive for our shareholders, we also have a new, important prime contract vehicle through which we plan to accelerate our organic growth. Jim Morton is an excellent addition to our management team and the roughly 60 new Castellum employees will augment our talent as we scale the business. We look forward to fully integrating GTMR into Castellum. We now shift our focus to closing our other pending non-binding LOI, which we expect to do within the next 10-20 days, as well as looking for our next acquisition.”

About Castellum, Inc.


Castellum, Inc.
(NYSE-American: CTM) is a defense-oriented technology company that is executing strategic acquisitions primarily in the cyber security and electronic warfare services space – http://castellumus.com/.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and other filings made by the Company and disclose at www.sec.gov. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements. Specifically, the future combined operating performance of Castellum and GTMR may not achieve its targeted results if the integration takes longer than expected or does not go as well as anticipated, and Castellum may not close on its other pending non-binding LOI as it is subject to execution of a definitive agreement or within the time stated in this press release.

Contact:

Skyline Corporate Communications Group, LLC
Lisa Gray, Senior Account Manager
One Rockefeller Plaza, 11th Floor
New York, NY 10020
Office: 646.893.5835 x1
Email: [email protected]; [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/34dafa3b-ba93-4837-b360-04ec382e9c71



Movado Group, Inc. Announces Fourth Quarter and Fiscal Year 2023 Results

Movado Group, Inc. Announces Fourth Quarter and Fiscal Year 2023 Results

~ Fiscal 2023 Net Sales of $751.9 million ~

~ Fiscal 2023 EPS of $4.12 and Fiscal 2023 Adjusted EPS of $4.22 ~

~ Fourth Quarter Net Sales of $194.3 million ~

~ Fourth Quarter EPS of $1.00 and Fourth Quarter Adjusted EPS of $1.03 ~

~ Board Declares Special Dividend in Addition to Regular Quarterly Dividend ~

PARAMUS, N.J.–(BUSINESS WIRE)–
Movado Group, Inc. (NYSE: MOV) today announced fourth quarter and fiscal year 2023 results for the periods ended January 31, 2023.

Fiscal Year 2023 Highlights (See attached table for GAAP and Non-GAAP measures)

  • Delivered topline growth of 2.7% or 7.0% on a constant dollar basis year over year;
  • Generated gross margin of 57.7% as compared to 57.2% last year;
  • Generated operating income of $120.4 million as compared to $117.5 million in the prior year. Adjusted operating income was $123.2 million as compared to adjusted operating income of $119.7 million in fiscal 2022;
  • Achieved diluted earnings per share of $4.12 as compared to $3.87 in the prior year. Adjusted diluted earnings per share was $4.22 as compared to $3.94 in fiscal 2022; and
  • Ended the year with cash of $251.6 million and no debt.

Efraim Grinberg, Chairman and Chief Executive Officer, stated, “We managed our business well throughout the year, driving Movado Group to a record year for net sales and operating income with expansion in gross profit margin, as compared to fiscal 2022. We achieved this while generating fourth quarter results that, as expected, moderated from the fourth quarter of the prior year. These results follow a record performance in fiscal 2022 and reflect the power of our global portfolio of brands and the disciplined execution of our strategy by our organization. I am extremely proud of our teams for their contributions in the current operating environment.”

Mr. Grinberg continued, “As we look ahead, we believe we will continue to face a difficult retail market in our largest regions, the U.S. and Europe. We have a strong portfolio of brands that we will continue to support with strong product innovation and marketing programs. While we continue to maintain a disciplined approach to managing expenses and inventory levels, we will make the marketing investments behind our biggest brands to ensure that we emerge from the current environment in the strongest position and lay a solid foundation for future growth. Our strong balance sheet, with over $251 million in cash and no debt, allows us to navigate through this period of uncertainty while continuing to invest behind our brands, our teams and our customers. We are pleased that our Board of Directors approved a special dividend of $1.00 per share, in addition to our regular quarterly dividend of $0.35 per share, demonstrating confidence in the future performance of our business and returning value to our shareholders.”

Fiscal Fourth Quarter Highlights (See attached table for GAAP and Non-GAAP measures)

  • Delivered net sales of $194.3 million versus $206.0 million in the prior year period;
  • Generated gross margin of 56.2% as compared to 58.7% in the fourth quarter of fiscal 2022;
  • Generated operating income of $26.1 million as compared to $38.2 million in the prior year period. Adjusted operating income was $26.8 million as compared to adjusted operating income of $37.9 million in the fourth quarter of fiscal 2022; and
  • Achieved diluted earnings per share of $1.00 as compared to $1.33 in the prior year period. Adjusted diluted earnings per share was $1.03 as compared to $1.32 in the fourth quarter of fiscal 2022.

Non-GAAP Items (See attached table for GAAP and Non-GAAP measures)

Fourth quarter fiscal 2023 results of operations included the following charges:

  • a $0.6 million pre-tax charge, or $0.5 million after tax, representing $0.02 per diluted share, associated with the amortization of acquired intangible assets related to the acquisition of Olivia Burton; and
  • a $0.1 million pre-tax and after-tax charge, representing $0.00 per diluted share, associated with the amortization of acquired intangible assets and deferred compensation related to the acquisition of MVMT.

Fourth quarter fiscal 2022 results of operations included the following charges and benefits:

  • a $0.7 million pre-tax charge, or $0.6 million after tax, representing $0.03 per diluted share, associated with the amortization of acquired intangible assets related to the acquisition of Olivia Burton;
  • a $0.1 million pre-tax and after-tax charge, representing $0.00 per diluted share, associated with the amortization of acquired intangible assets and deferred compensation related to the acquisition of MVMT; and
  • a $1.1 million pre-tax benefit, or $0.8 million after tax, representing $0.04 per diluted share, due to a change in estimate related to corporate initiative charges recorded primarily in response to the COVID-19 pandemic.

In this press release, references to “adjusted” results exclude the impact of the above charges and benefits, as well as the items described in the Non-GAAP Items section of the Company’s earnings releases for the first, second and third quarter of fiscal year 2023, in deriving the adjusted results for the twelve months ended January 31, 2023 and January 31, 2022. Please refer to the attached GAAP and Non-GAAP measures table for a detailed reconciliation of the Company’s reported results to its adjusted, non-GAAP results.

Fourth Quarter Fiscal 2023 Results (See attached table for GAAP and Non-GAAP measures)

  • Net sales decreased 5.7% to $194.3 million, or decreased 2.8% on a constant dollar basis, compared to $206.0 million in the fourth quarter of fiscal 2022. The decrease in net sales reflected a decline in wholesale sales, partially offset by an increase in Movado Company stores. U.S. net sales decreased 6.3% as compared to the fourth quarter of last year. International net sales decreased 5.0% as compared to the fourth quarter of last year and increased 0.6% on a constant dollar basis as compared to the prior year period.
  • Gross profit was $109.3 million, or 56.2% of net sales, compared to $120.8 million, or 58.7% of net sales in the fourth quarter of fiscal 2022. The decrease in gross margin percentage was primarily the result of the unfavorable changes in channel and product mix and unfavorable impact of foreign currency exchange rates.
  • Operating expenses increased to $83.1 million in the fourth quarter of fiscal 2023 from $82.6 million in the fourth quarter of fiscal 2022. Adjusted operating expenses were $82.4 million compared to $82.9 million in the prior year period. This decrease was primarily due to lower performance-based compensation, partially offset by higher payroll-related expenses and higher marketing expenses. As a percent of sales, adjusted operating expenses increased to 42.4% of sales from 40.3% in the prior year period due to lower sales.
  • Operating income was $26.1 million compared to $38.2 million in the fourth quarter of fiscal 2022. Adjusted operating income was $26.8 million for the fourth quarter of fiscal 2023 and $37.9 million for the prior year period.
  • The Company recorded a tax provision of $4.0 million, as compared to a tax provision of $6.6 million in the fourth quarter of fiscal 2022. Based upon adjusted pre-tax income, the adjusted tax provision was $4.2 million, or an adjusted tax rate of 14.8%, as compared to an adjusted tax provision of $6.5 million, or an adjusted tax rate of 17.1%, in the fourth quarter of fiscal 2022.
  • Net income for the fourth quarter of fiscal 2023 was $22.7 million, or $1.00 per diluted share, compared to net income of $31.4 million, or $1.33 per diluted share, in the fourth quarter of fiscal 2022. Adjusted net income for the fiscal 2023 period was $23.3 million, or $1.03 per diluted share, compared to adjusted net income of $31.2 million, or $1.32 per diluted share, for the fourth quarter of fiscal 2022.

Full Year Fiscal 2023 Results (See attached table for GAAP and Non-GAAP measures)

  • Net sales increased 2.7% to $751.9 million, or increased 7.0% on a constant dollar basis, compared to net sales of $732.4 million in fiscal 2022. The increase in net sales reflected growth in the International wholesale business and Movado Company Stores. U.S. net sales decreased 3.5% compared to last year. International net sales increased 8.2% as compared to last year and increased 16.4% on a constant currency basis.
  • Gross profit was $433.9 million, or 57.7% of net sales, compared to gross profit of $419.1 million, or 57.2% of net sales, in fiscal 2022. The year over year increase in gross margin percentage was primarily the result of favorable changes in channel and product mix, partially offset by unfavorable impact of foreign currency exchange rates and increased shipping costs.
  • Operating expenses were $313.5 million in fiscal 2023 compared to $301.6 million in fiscal 2022. For fiscal 2023, adjusted operating expenses were $310.7 million versus $299.4 million in fiscal 2022. This increase was primarily due to higher payroll-related costs, higher marketing expenses and certain other operating expenses to support the increase in net sales, partially offset by lower performance-based compensation.
  • Operating income was $120.4 million in fiscal 2023 as compared to operating income of $117.5 million in fiscal 2022. Adjusted operating income for fiscal 2023 was $123.2 million compared to adjusted operating income for fiscal 2022 of $119.7 million.
  • The tax provision was $24.9 million in fiscal 2023 compared to a tax provision of $24.8 million in fiscal 2022. Based upon adjusted pre-tax income, the adjusted tax provision was $25.4 million, or an adjusted effective tax rate of 20.4% in fiscal 2023, as compared to an adjusted tax provision of $25.2 million, or an adjusted effective tax rate of 21.1% in fiscal 2022.
  • Net income was $94.5 million, or $4.12 per diluted share, for fiscal 2023, compared to net income of $91.6 million, or $3.87 per diluted share, for fiscal 2022. Adjusted net income in fiscal 2023 was $96.8 million or $4.22 per diluted share. This compares to adjusted net income for fiscal 2022 of $93.4 million or $3.94 per diluted share.

Fiscal 2024 Outlook

The Company expects fiscal 2024 net sales to be in a range of approximately $725.0 million to $750.0 million, gross profit of approximately 56.0% of net sales, and operating income in a range of $80.0 million to $85.0 million. Assuming no changes to the current tax regulations, the Company anticipates an effective tax rate of approximately 22% for the fiscal year and earnings of $2.70 to $2.90 per diluted share. The outlook excludes approximately $2.1 million of amortization of acquired intangible assets for fiscal 2024 related to the Olivia Burton and MVMT brands. For the first half of fiscal 2024, the Company expects sales to decline in a range of 9% to 12% relative to the prior-year period as it anniversaries the record first half results of fiscal 2023. This outlook does not contemplate further deterioration due to the impact of economic uncertainty, and assumes no further significant fluctuations from prevailing foreign currency exchange rates.

Special Dividend, Quarterly Dividend and Share Repurchase Program

The Company also announced today that on March 23, 2023, the Board of Directors approved the payment on April 19, 2023 of a special cash dividend in the amount of $1.00 per share as well as the regular quarterly cash dividend in the amount of $0.35 per share. Both dividends are payable on each share of the Company’s outstanding common stock and class A common stock held by shareholders of record as of the close of business on April 5, 2023.

During the fourth quarter of fiscal 2023, the Company repurchased approximately 103,500 shares under its November 23, 2021 share repurchase program. As of January 31, 2023, the Company had $21.0 million remaining available under the share repurchase program.

Conference Call

The Company’s management will host a conference call and audio webcast to discuss its results today, March 23, 2023 at 9:00 a.m. Eastern Time. The conference call may be accessed by dialing (877) 407-0784. Additionally, a live webcast of the call can be accessed at www.movadogroup.com.The webcast will be archived on the Company’s website approximately one hour after the conclusion of the call. Additionally, a telephonic re-play of the call will be available from 12:00 p.m. ET on March 23, 2023 until 11:59 p.m. ET on April 6, 2023 and can be accessed by dialing 844-512-2921 and entering replay pin number 13736686.

Movado Group, Inc. designs, sources, and distributes MOVADO®, MVMT®, OLIVIA BURTON®, EBEL®, CONCORD®, CALVIN KLEIN®, COACH®, TOMMY HILFIGER®, HUGO BOSS®, and LACOSTE®, watches, and, to a lesser extent jewelry and other accessories, and operates Movado Company Stores in the United States and Canada.

In this release, the Company presents certain financial measures that are not calculated according to generally accepted accounting principles in the United States (“GAAP”). Specifically, the Company is presenting adjusted gross profit, adjusted gross margin, adjusted operating expenses, adjusted operating income, adjusted pre-tax income, adjusted tax provision and adjusted net income, which are gross profit, gross margin, operating expenses, operating income, pre-tax income, tax provision and net income, respectively, under GAAP, adjusted to eliminate the amortization of acquisition accounting adjustments related to the Olivia Burton and MVMT acquisitions and corporate initiatives. The Company is also presenting adjusted tax provision, which is the tax provision under GAAP, adjusted to eliminate the impact of charges for the Olivia Burton and MVMT acquisitions and corporate initiatives. The Company believes these adjusted measures are useful because they give investors information about the Company’s financial performance without the effect of certain items that the Company believes are not characteristic of its usual operations. The Company is also presenting adjusted net income, adjusted earnings per share and adjusted effective tax rate, which are net income, earnings per share and effective tax rate, respectively, under GAAP, adjusted to eliminate the after-tax impact of amortization of acquisition accounting adjustments related to the Olivia Burton and MVMT acquisitions and corporate initiatives. The Company believes that adjusted net income, adjusted earnings per share and adjusted effective tax rate are useful measures of performance because they give investors information about the Company’s financial performance without the effect of certain items that the Company believes are not characteristic of its usual operations. Additionally, the Company is presenting constant currency information to provide a framework to assess how its business performed excluding the effects of foreign currency exchange rate fluctuations in the current period. Comparisons of financial results on a constant dollar basis are calculated by translating each foreign currency at the same U.S. dollar exchange rate as in effect for the prior-year period for both periods being compared.The Company believes this information is useful to investors to facilitate comparisons of operating results. These non-GAAP financial measures are designed to complement the GAAP financial information presented in this release. The non-GAAP financial measures presented should not be considered in isolation from or as a substitute for the comparable GAAP financial measures, and the methods of their calculation may differ substantially from similarly titled measures used by other companies.

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as “expects,” “anticipates,” “believes,” “targets,” “goals,” “projects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “should” and variations of such words and similar expressions. Similarly, statements in this press release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals are also forward-looking statements. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause the Company’s actual results, performance or achievements and levels of future dividends to differ materially from those expressed in, or implied by, these statements. These risks and uncertainties may include, but are not limited to general economic and business conditions which may impact disposable income of consumers in the United States and the other significant markets (including Europe) where the Company’s products are sold, uncertainty regarding such economic and business conditions, including inflation, increased commodity prices and tightness in the labor market, trends in consumer debt levels and bad debt write-offs, general uncertainty related to possible terrorist attacks, natural disasters and pandemics, including the effect of the COVID-19 pandemic and other diseases on travel and traffic in the Company’s retail stores and the stores of its wholesale customers, supply disruptions, delivery delays and increased shipping costs, adverse impact on the Company’s wholesale customers and customer traffic in the Company’s stores as a result of increased uncertainty and economic disruption caused by the COVID-19 pandemic, the impact of international hostilities, including the Russian invasion of Ukraine, on global markets, economies and consumer spending, on energy and shipping costs and on the Company’s supply chain and suppliers, defaults on or downgrades of sovereign debt and the impact of any of those events on consumer spending, changes in consumer preferences and popularity of particular designs, new product development and introduction, decrease in mall traffic and increase in e-commerce, the ability of the Company to successfully implement its business strategies, competitive products and pricing, including price increases to offset increased costs, the impact of “smart” watches and other wearable tech products on the traditional watch market, seasonality, availability of alternative sources of supply in the case of the loss of any significant supplier or any supplier’s inability to fulfill the Company’s orders, the loss of or curtailed sales to significant customers, the Company’s dependence on key employees and officers, the ability to successfully integrate the operations of acquired businesses without disruption to other business activities, the possible impairment of acquired intangible assets, risks associated with the Company’s minority investments in early-stage growth companies and venture capital funds that invest in such companies; the continuation of the Company’s major warehouse and distribution centers, the continuation of licensing arrangements with third parties, losses possible from pending or future litigation and administrative proceedings, the ability to secure and protect trademarks, patents and other intellectual property rights, the ability to lease new stores on suitable terms in desired markets and to complete construction on a timely basis, the ability of the Company to successfully manage its expenses on a continuing basis, information systems failure or breaches of network security, complex and quickly-evolving regulations regarding privacy and data protection, the continued availability to the Company of financing and credit on favorable terms, business disruptions, and general risks associated with doing business outside the United States including, without limitation, import duties, tariffs (including retaliatory tariffs), quotas, political and economic stability, changes to existing laws or regulations, and success of hedging strategies with respect to currency exchange rate fluctuations, and the other factors discussed in the Company’s Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. These statements reflect the Company’s current beliefs and are based upon information currently available to it. Be advised that developments subsequent to this press release are likely to cause these statements to become outdated with the passage of time. The Company assumes no duty to update its forward looking statements and this release shall not be construed to indicate the assumption by the Company of any duty to update its outlook in the future.

(Tables to follow)

MOVADO GROUP, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

 
 

Three Months Ended

Twelve Months Ended

January 31,

January 31,

 

2023

2022

2023

2022

 
Net sales

$

194,273

 

$

205,975

 

$

751,898

 

$

732,393

 

 
Cost of sales

 

85,017

 

 

85,139

 

 

318,003

 

 

313,328

 

 
Gross profit

 

109,256

 

 

120,836

 

 

433,895

 

 

419,065

 

 
Total operating expenses

 

83,124

 

 

82,637

 

 

313,541

 

 

301,574

 

 
Operating income

 

26,132

 

 

38,199

 

 

120,354

 

 

117,491

 

 
Non-operating income/(expense):
Other income

 

1,365

 

 

87

 

 

2,069

 

 

530

 

Interest expense

 

(162

)

 

(106

)

 

(518

)

 

(688

)

 
Income before income taxes

 

27,335

 

 

38,180

 

 

121,905

 

 

117,333

 

 
Provision for income taxes

 

4,014

 

 

6,568

 

 

24,882

 

 

24,774

 

 
Net income

 

23,321

 

 

31,612

 

 

97,023

 

 

92,559

 

 
Less: Net income attributable to noncontrolling interests

 

595

 

 

237

 

 

2,495

 

 

960

 

 
Net income attributable to Movado Group, Inc.

$

22,726

 

$

31,375

 

$

94,528

 

$

91,599

 

 
Diluted Income Per Share Information
Net income attributable to Movado Group, Inc.

$

1.00

 

$

1.33

 

$

4.12

 

$

3.87

 

 
Weighted diluted average shares outstanding

 

22,708

 

 

23,629

 

 

22,955

 

 

23,679

 

 
MOVADO GROUP, INC.
GAAP AND NON-GAAP MEASURES
(In thousands, except for percentage data)
(Unaudited)
 
 

As Reported

Three Months Ended

January 31,

% Change

 

2023

2022

 
Total net sales, as reported

$

194,273

$

205,975

-5.7%

 
Total net sales, constant dollar basis

$

200,116

$

205,975

-2.8%

 
 
 

As Reported

Twelve Months Ended

January 31,

% Change

 

2023

2022

 
Total net sales, as reported

$

751,898

$

732,393

2.7%

 
Total net sales, constant dollar basis

$

783,680

$

732,393

7.0%

 

MOVADO GROUP, INC.

GAAP AND NON-GAAP MEASURES

(In thousands, except per share data)

(Unaudited)

 

Net Sales

Gross Profit

Total

Operating

Expenses

Operating

Income/(Loss)

Pre-tax

Income/(Loss)

Provision/(Benefit)

for Income Taxes

Net Income/(Loss)

Attributable to

Movado Group, Inc.

Diluted EPS

Three Months Ended January 31, 2023
As Reported (GAAP)

$

194,273

$

109,256

$

83,124

 

$

26,132

 

$

27,335

 

$

4,014

 

$

22,726

 

$

1.00

 

Olivia Burton Costs (1)

 

 

 

(627

)

 

627

 

 

627

 

 

119

 

 

508

 

 

0.02

 

MVMT Costs (2)

 

 

 

(71

)

 

71

 

 

71

 

 

17

 

 

54

 

 

0.00

 

Adjusted Results (Non-GAAP)

$

194,273

$

109,256

$

82,426

 

$

26,830

 

$

28,033

 

$

4,150

 

$

23,288

 

$

1.03

 

 
 
Three Months Ended January 31, 2022
As Reported (GAAP)

$

205,975

$

120,836

$

82,637

 

$

38,199

 

$

38,180

 

$

6,568

 

$

31,375

 

$

1.33

 

Olivia Burton Costs (1)

 

 

 

(699

)

 

699

 

 

699

 

 

133

 

 

566

 

 

0.03

 

MVMT Costs (2)

 

 

 

(89

)

 

89

 

 

89

 

 

22

 

 

67

 

 

0.00

 

Corporate Initiatives (3)

 

 

 

1,064

 

 

(1,064

)

 

(1,064

)

 

(231

)

 

(833

)

 

(0.04

)

Adjusted Results (Non-GAAP)

$

205,975

$

120,836

$

82,913

 

$

37,923

 

$

37,904

 

$

6,492

 

$

31,175

 

$

1.32

 

 
 

Net Sales

Gross Profit

Total

Operating

Expenses

Operating

Income/(Loss)

Pre-tax

Income/(Loss)

Provision/(Benefit)

for Income Taxes

Net Income/(Loss)

Attributable to

Movado Group, Inc.

Diluted EPS

Twelve Months Ended January 31, 2023
As Reported (GAAP)

$

751,898

$

433,895

$

313,541

 

$

120,354

 

$

121,905

 

$

24,882

 

$

94,528

 

$

4.12

 

Olivia Burton Costs (1)

 

 

 

(2,551

)

 

2,551

 

 

2,551

 

 

485

 

 

2,066

 

 

0.09

 

MVMT Costs (2)

 

 

 

(299

)

 

299

 

 

299

 

 

72

 

 

227

 

 

0.01

 

Adjusted Results (Non-GAAP)

$

751,898

$

433,895

$

310,691

 

$

123,204

 

$

124,755

 

$

25,439

 

$

96,821

 

$

4.22

 

 
 
Twelve Months Ended January 31, 2022
As Reported (GAAP)

$

732,393

$

419,065

$

301,574

 

$

117,491

 

$

117,333

 

$

24,774

 

$

91,599

 

$

3.87

 

Olivia Burton Costs (1)

 

 

 

(2,860

)

 

2,860

 

 

2,860

 

 

544

 

 

2,316

 

 

0.10

 

MVMT Costs (2)

 

 

 

(424

)

 

424

 

 

424

 

 

106

 

 

318

 

 

0.01

 

Corporate Initiatives (3)

 

 

 

1,064

 

 

(1,064

)

 

(1,064

)

 

(231

)

 

(833

)

 

(0.04

)

Adjusted Results (Non-GAAP)

$

732,393

$

419,065

$

299,354

 

$

119,711

 

$

119,553

 

$

25,193

 

$

93,400

 

$

3.94

 

(1)

Related to the amortization of acquired intangible assets for Olivia Burton.

(2)

Related to the amortization of acquired intangible assets and the MVMT brand’s deferred compensation, where applicable.

(3)

Related to a change in estimate related to corporate initiative charges recorded primarily in response to the COVID-19 pandemic.

 

MOVADO GROUP, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

 

January 31,

January 31,

2023

2022

ASSETS
 
 
Cash and cash equivalents

$

251,584

$

277,128

Trade receivables, net

 

94,282

 

91,558

Inventories

 

186,203

 

160,283

Other current assets

 

24,212

 

16,974

Income taxes receivable

 

10,908

 

7,941

Total current assets

 

567,189

 

553,884

 
Property, plant and equipment, net

 

18,699

 

19,470

Operating lease right-of-use assets

 

80,897

 

68,599

Deferred and non-current income taxes

 

44,490

 

42,596

Other intangibles, net

 

9,642

 

13,507

Other non-current assets

 

66,788

 

63,104

Total assets

$

787,705

$

761,160

 
LIABILITIES AND EQUITY
 
 
Accounts payable

$

32,085

$

46,011

Accrued liabilities

 

46,720

 

48,522

Accrued payroll and benefits

 

17,343

 

25,117

Current operating lease liabilities

 

17,681

 

13,693

Income taxes payable

 

28,591

 

18,123

Total current liabilities

 

142,420

 

151,466

 
Deferred and non-current income taxes payable

 

15,163

 

19,614

Non-current operating lease liabilities

 

70,910

 

62,730

Other non-current liabilities

 

48,668

 

50,264

 
Redeemable noncontrolling interest

 

 

2,311

 
Shareholders’ equity

 

507,606

 

472,808

 
Noncontrolling interest

 

2,938

 

1,967

Total equity

 

510,544

 

474,775

 
Total liabilities, redeemable noncontrolling interest and equity

$

787,705

$

761,160

 

MOVADO GROUP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

Twelve Months Ended

January 31,

 

2023

2022

Cash flows from operating activities:
Net income

$

97,023

 

$

92,559

 

Non-cash corporate initiatives

 

 

 

(926

)

Depreciation and amortization

 

10,809

 

 

12,463

 

Other non-cash adjustments

 

9,540

 

 

9,292

 

Changes in working capital

 

(58,650

)

 

13,487

 

Changes in non-current assets and liabilities

 

(4,381

)

 

3,939

 

Net cash provided by operating activities

 

54,341

 

 

130,814

 

 
Cash flows from investing activities:
Capital expenditures

 

(7,085

)

 

(5,656

)

Long-term investments

 

(3,263

)

 

(1,967

)

Trademarks and other intangibles

 

(202

)

 

(291

)

Net cash used in investing activities

 

(10,550

)

 

(7,914

)

 
Cash flows from financing activities:
Repayment of bank borrowings

 

 

 

(21,140

)

Dividends paid

 

(31,363

)

 

(21,973

)

Stock repurchase

 

(31,413

)

 

(22,599

)

Purchase of incremental ownership of joint venture

 

(1,886

)

 

 

Distribution of noncontrolling interest earnings

 

(1,056

)

 

(1,230

)

Stock awards and options exercised and other changes

 

489

 

 

324

 

Contributions from noncontrolling interest

 

 

 

298

 

Debt issuance cost

 

(85

)

 

(294

)

Net cash used in financing activities

 

(65,314

)

 

(66,614

)

 
Effect of exchange rate changes on cash, cash equivalents, and restricted cash

 

(4,014

)

 

(2,993

)

Net change in cash, cash equivalents, and restricted cash

 

(25,537

)

 

53,293

 

Cash, cash equivalents, and restricted cash at beginning of period

 

277,716

 

 

224,423

 

 
Cash, cash equivalents, and restricted cash at end of period

$

252,179

 

$

277,716

 

 
Reconciliation of cash, cash equivalents, and restricted cash:
Cash and cash equivalents

$

251,584

 

$

277,128

 

Restricted cash included in other non-current assets

 

595

 

 

588

 

Cash, cash equivalents, and restricted cash

$

252,179

 

$

277,716

 

 

ICR, Inc.

Rachel Schacter/Allison Malkin

203-682-8200

KEYWORDS: United States North America New Jersey

INDUSTRY KEYWORDS: Retail Luxury Jewelry

MEDIA:

Chemours Appoints Denise Dignam President, Titanium Technologies & Chemical Solutions, Gerardo Familiar Named President, Advanced Performance Materials

Chemours Appoints Denise Dignam President, Titanium Technologies & Chemical Solutions, Gerardo Familiar Named President, Advanced Performance Materials

Business strategies are unchanged as the company promotes top executives

WILMINGTON, Del.–(BUSINESS WIRE)–
The Chemours Company (“Chemours”) (NYSE: CC), a global chemistry company with leading market positions in Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials, announces the appointment of Denise Dignam as President, Chemours Titanium Technologies and Chemical Solutions, effective April 1, 2023. Chemours will promote Gerardo Familiar to succeed Ms. Dignam as President, Chemours Advanced Performance Materials.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230323005149/en/

Denise Dignam, President, Chemours Titanium Technologies and Chemical Solutions (Photo: Business Wire)

Denise Dignam, President, Chemours Titanium Technologies and Chemical Solutions (Photo: Business Wire)

“Chemours is fortunate to have tremendous internal talent from which to draw in order to fill these key leadership positions,” said Mark Newman, Chemours President and Chief Executive Officer. “Both Denise and Gerardo are proven leaders who have helped to drive strong business performance and embrace our passion for producing critical chemistries that are innovative, responsibly manufactured, and play an essential role in a more sustainable economy.”

Denise Dignam brings more than 30 years of chemical industry experience to her new role leading Chemours’ largest business segment and Chemical Solutions business. Her expertise spans commercialization, sales, marketing, strategy, supply chain, and operations. She was named to lead the Advanced Performance Materials (APM) segment in 2021 and under her leadership, the segment achieved record Net Sales, Adjusted EBITDA, and Adjusted EBITDA Margin. During her tenure, APM has accelerated growth initiatives in clean energy and advanced electronics, announced strategic partnerships and initiatives in North America and Europe, and reshaped the product portfolio from advanced materials to performance solutions to drive long term growth.

Gerardo Familiar has more than two decades of experience in the chemicals sector. He is currently general manager for the Chemours hydrogen venture where he has been central to accelerating Chemours’ growth initiatives in clean energy and hydrogen solutions. Prior to that, he led Global Strategy, Marketing, and Regulatory Affairs for Thermal & Specialized Solutions (TSS). In his time with Chemours, Mr. Familiar was also Investor Relations director, and served simultaneously as president of Chemours Mexico and Latin Americas business director for both the APM and TSS segments. He was previously global business director for the Teflon™ business, held several sales and marketing positions within the fluorinated chemistries segments. And he spent almost ten years as a consultant focused on business strategy, process improvement and value-based management.

Mr. Newman added, “As I reflect on the strength of our three businesses and the depth and diversity of our leadership team, I am excited about Chemours’ ability to continue delivering significant value to our stakeholders in the coming years.”

About The Chemours Company

The Chemours Company (NYSE: CC) is a global leader in Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials providing its customers with solutions in a wide range of industries with market-defining products, application expertise and chemistry-based innovations. We deliver customized solutions with a wide range of industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, general industrial, and oil and gas. Our flagship products are sold under prominent brands such as Ti-Pure™, Opteon™, Freon™, Teflon™, Viton™, Nafion™, and Krytox™. The company has approximately 6,600 employees and 29 manufacturing sites serving approximately 2,900 customers in approximately 120 countries. Chemours is headquartered in Wilmington, Delaware and is listed on the NYSE under the symbol CC.

For more information, we invite you to visit chemours.com or follow us on Twitter @Chemours or LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words “believe,” “expect,” “will,” “anticipate,” “plan,” “estimate,” “target,” “project” and similar expressions, among others, generally identify “forward-looking statements,” which speak only as of the date such statements were made. These forward-looking statements may address, among other things, the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, anticipated future operating and financial performance for our segments individually and our company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, plans for dividends or share repurchases, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as full year guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours’ control. In addition, the COVID-19 pandemic has significantly impacted the national and global economy and commodity and financial markets, which has had and we expect will continue to have a negative impact on our financial results. The full extent and impact of the pandemic is still being determined and to date has included significant volatility in financial and commodity markets and a severe disruption in economic activity. The public and private sector response has led to travel restrictions, temporary business closures, quarantines, stock market volatility, and interruptions in consumer and commercial activity globally. Matters outside our control, including general economic conditions, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2022. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

INVESTORS

Jonathan Lock

SVP, Chief Development Officer

+1.302.773.2263

[email protected]

Kurt Bonner

Manager, Investor Relations

+1.302.773.0026

[email protected]

NEWS MEDIA

Thom Sueta

Director, Corporate Communications

+1.302.773.3903

KEYWORDS: Delaware United States North America

INDUSTRY KEYWORDS: Engineering Chemicals/Plastics Manufacturing Other Science Other Manufacturing Research Science

MEDIA:

Logo
Logo
Photo
Photo
Denise Dignam, President, Chemours Titanium Technologies and Chemical Solutions (Photo: Business Wire)
Photo
Photo
Gerardo Familiar, President, Chemours Advanced Performance Materials (Photo: Business Wire)